Abstract:

Title: VACCINATION WITH INTERLEUKIN-4 ANTAGONISTS

5.2(a) with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
Vaccination with Interleukin-4 Antagonists

Incorporation by Cross-Reference

The present application claims priority from Australian provisional patent application number 2012902345 filed on 5 June 2012, the entire contents of which are incorporated herein by cross-reference.

Technical Field

The present invention relates generally to the field of immunology. More specifically, the present invention relates to compositions and methods for enhancing antigen-specific immune responses. The compositions and methods find particular application in the prevention and/or treatment of various diseases including, but not limited to, infectious diseases.

Background

It is widely felt that potent antiviral mucosal CD8+ cytotoxic T lymphocytes (CTL) should be a major component of an immune response induced by viral vaccines. In particular, the importance of local antiviral immune responses at mucosal surfaces is becoming increasingly clear. It is also becoming increasingly evident that not only the magnitude but also the 'quality' or avidity of the antiviral T-cell responses may be important in protecting against viral infection, particularly those proven to be resistant to existing immunisation strategies. The quality of the T-cell response may be reflected in the functional avidity of T cells towards the MHC-peptide complex on target cells. High-avidity CTL can recognise low concentrations of antigen, while low-avidity CTL are inefficient in effector function at low concentrations of antigen. It has been established that high-avidity CTL have increased functional capacity to clear infection compared with low-avidity T cells. However, the relative ratio of high- and low-avidity CTL has been observed to change over the course of infection. Nonetheless, it well recognised that high avidity CTL have a greater ability to clear an infection than low avidity T cells.

For example, in the case of human immunodeficiency virus (HIV) local antiviral immune responses in the genital and rectal tissues where HIV is usually first encountered are vital. Local immune responses in the gastro-intestinal tract are also important given that it is a major site of HIV replication. The presence of high-avidity antiviral T cells at
sites of initial HIV exposure (mucosa) offers the potential for reducing mucosal CD4+ T-cell depletion and local control of HIV infection. Given their demonstrated capacity to recognise target cells expressing very low levels of viral antigen (e.g. early after infection of a cell), and their more rapid initiation of target cell lysis at low concentrations of target antigen, vaccine strategies that elicit high-avidity CTL are potentially likely to offer greater protection against infection.

A need exists for antiviral vaccines capable of eliciting high-avidity CTL. In particular, there is a need for antiviral vaccines capable of eliciting high-avidity CTL at mucosal surfaces which are the initial point of infection for many viruses.

**Summary of the Invention**

The present inventors have discovered that both the magnitude and avidity of antigen-specific T lymphocytes induced by antiviral vaccines can be increased by transiently reducing the availability of interleukin-4 (IL-4) and/or transiently inhibiting IL-4 function.

In a first aspect, the present invention provides a method for inducing an antigen-specific immune response in a subject, the method comprising administering the antigen to the subject in combination with an interleukin-4 receptor (IL-4R) antagonist.

In a second aspect, the present invention provides a method for increasing the avidity of immune cells for an antigen in a subject, the method comprising administering the antigen to the subject in combination with an interleukin-4 receptor (IL-4R) antagonist.

In a third aspect, the present invention provides a method for increasing the number of immune cells specific for an antigen in a subject, the method comprising administering the antigen to the subject in combination with an interleukin-4 receptor (IL-4R) antagonist.

In one embodiment of the above aspects, the method comprises administering a priming dose and a booster dose to the subject, each said dose comprising administering the antigen to the subject in combination with the interleukin-4 receptor (IL-4R) antagonist.

In one embodiment of the above aspects, the method comprises administering a priming dose to the subject, wherein the priming dose comprises the antigen and an IL-4R antagonist.
In one embodiment of the above aspects, the method comprises administering a booster dose to the subject, wherein the booster dose comprises the antigen and an IL-4R antagonist.

In one embodiment of the above aspects, the antigen and IL-4R antagonist of the booster dose may be administered sequentially or simultaneously.

In one embodiment of the above aspects, administering the primer dose comprises administering a polynucleotide encoding the antigen, a polynucleotide encoding the IL-4R antagonist, or both.

In one embodiment of the above aspects, administering the booster dose comprises administering a polynucleotide encoding the antigen, a polynucleotide encoding the IL-4R antagonist, or both.

In one embodiment of the above aspects, any one or more of the polynucleotides in the primer dose may be a component of a recombinant virus.

In one embodiment of the above aspects, any one or more of the polynucleotides in the booster dose may be a component of a recombinant virus.

In one embodiment of the above aspects, the recombinant virus of the primer dose is a poxvirus.

In one embodiment of the above aspects, the recombinant virus of the booster dose is a poxvirus.

In one embodiment of the above aspects, the recombinant virus of the primer dose is a poxvirus selected from the group consisting of a vaccinia virus, an attenuated vaccinia virus (e.g. NYVAC), a fowlpox virus, a canarypox virus, and a modified vaccinia ankara (MVA) virus.

In one embodiment of the above aspects, the recombinant virus of the booster dose is a poxvirus selected from the group consisting of a vaccinia virus, an attenuated vaccinia virus (e.g. NYVAC), a fowlpox virus, a canarypox virus, and a modified vaccinia ankara (MVA) virus.

In one embodiment of the above aspects, the IL-4R antagonist of the primer dose is an interleukin-4 receptor alpha chain (IL-4Ret) antagonist capable of binding to IL-4Ra and preventing IL-4R signalling.

In one embodiment of the above aspects, the IL-4R antagonist of the booster dose is an interleukin-4 receptor alpha chain (IL-4Ra) antagonist capable of binding to IL-4Ra and preventing IL-4R signalling.

In one embodiment of the above aspects, the IL-4R antagonist of the primer dose is a human interleukin-4 molecule lacking a signal peptide and comprising one or more
mutations selected from: a mutation at residue 121, a mutation at residue 124, a deletion of one or more residues after position 123, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

In one embodiment of the above aspects, the IL-4R antagonist of the booster dose is a human interleukin-4 molecule lacking a signal peptide and comprising one or more mutations selected from: a mutation at residue 121, a mutation at residue 124, a deletion of one or more residues after position 123, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

In one embodiment of the above aspects, the IL-4R antagonist of the primer dose is a human interleukin-4 molecule comprising a mutation selected from: R121D, Y124D, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

In one embodiment of the above aspects, the IL-4R antagonist of the booster dose is a human interleukin-4 molecule comprising a mutation selected from: R121D, Y124D, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

In one embodiment of the above aspects, the administering comprises administering a polynucleotide encoding the antigen, a polynucleotide encoding the interleukin-4 receptor antagonist, or both.

In one embodiment of the above aspects, any one or more of said polynucleotides is a component of a recombinant virus.

In one embodiment of the above aspects, the recombinant virus is a poxvirus.

In one embodiment of the above aspects, the recombinant virus is a poxvirus selected from the group consisting of a vaccinia virus, an attenuated vaccinia virus (e.g. NYVAC), a fowlpox virus, a canarypox virus, and a modified vaccinia ankara virus.

In one embodiment of the above aspects, the recombinant virus transiently expresses the interleukin-4 receptor (IL-4R) antagonist in the subject.

In one embodiment of the above aspects, the administering of the antigen to the subject in combination with an interleukin-4 receptor (IL-4R) antagonist decreases the number of CD103+, b220+, CD8cc+ cells in the subject and/or increases CD1 lb+, CD103-,b220-, CD8a - cells in the subject. The CD103+, b220+, CD8a+ cells and/or CD1 lb+, CD103-, b220-, CD8a - cells may be specific for the antigen. The antigen may be an HIV antigen (e.g. HIV gag, pol and/or env antigen).
In a fourth aspect, the present invention provides the use of an antigen and an interleukin-4 receptor (IL-4R) antagonist in the manufacture of a medicament for inducing a specific immune response against the antigen in a subject.

In a fifth aspect, the present invention provides the use of an antigen and an interleukin-4 receptor (IL-4R) antagonist in the manufacture of a medicament for increasing the avidity of immune cells specific for the antigen in a subject.

In a sixth aspect, the present invention provides the use of an antigen and an interleukin-4 receptor (IL-4R) antagonist in the manufacture of a medicament for increasing the number of immune cells specific for the antigen in a subject.

In a seventh aspect, the present invention provides an antigen and an interleukin-4 receptor (IL-4R) antagonist for use in inducing a specific immune response against the antigen in a subject.

In an eighth aspect, the present invention provides an antigen and an interleukin-4 receptor (IL-4R) antagonist for use in increasing the avidity of immune cells specific for the antigen in a subject.

In a ninth aspect, the present invention provides an antigen and an interleukin-4 receptor (IL-4R) antagonist for use in increasing the number of immune cells specific for the antigen in a subject.

In one embodiment of the fourth, fifth, sixth, seventh, eighth, and ninth aspects, the antigen is provided as a polynucleotide encoding the antigen.

In one embodiment of the fourth, fifth, sixth, seventh, eighth, and ninth aspects, the interleukin-4 receptor antagonist is provided a polynucleotide encoding the interleukin-4 receptor antagonist.

In one embodiment of the fourth, fifth, sixth, seventh, eighth, and ninth aspects, any one or more of said polynucleotides is a component of a recombinant virus.

In one embodiment of the fourth, fifth, sixth, seventh, eighth, and ninth aspects, the recombinant virus is a poxvirus.

In one embodiment of the fourth, fifth, sixth, seventh, eighth, and ninth aspects, the recombinant virus is a poxvirus selected from the group consisting of a vaccinia virus, an attenuated vaccinia virus (e.g. NYVAC), a fowlpox virus, a canarypox virus, and a modified vaccinia ankara virus.

In one embodiment of the fourth, fifth, sixth, seventh, eighth, and ninth aspects, the recombinant virus transiently expresses the interleukin-4 receptor (IL-4R) antagonist in the subject.
In one embodiment of the fourth, fifth, and sixth aspects, the medicament is a vaccine.

In one embodiment of the fourth, fifth, and sixth aspects, the medicament is a vaccine comprising first and second components, wherein the first component comprises the interleukin-4 receptor (IL-4R) antagonist and the second component comprises the antigen, and wherein the first and second components are for, or are formulated for, simultaneous or sequential administration to the subject.

In one embodiment of the seventh, eighth, and ninth aspects, aspects, the antigen and interleukin-4 receptor (IL-4R) antagonist are components of a vaccine.

In one embodiment of the fourth, fifth, sixth, seventh, eighth and ninth aspects, the vaccine is for administration to the subject, or formulated for administration to the subject, as a primer dose, a booster dose, or both.

In one embodiment of the fourth, fifth, sixth, seventh, eight and ninth aspects, the vaccine is capable of decreasing the number of GDI103+, b220+, CD8cc+ cells in the subject and/or increasing CI lb+, CD103-,b220-, CD8a - cells in the subject, upon administration to the subject. The CD103+, b220+, CD8a+ cells and/or CD1 lb+, CD103-, b220-, CD8a - cells may be specific for the antigen. The antigen may be an HIV antigen (e.g. HIV gag, pol and/or env antigen).

In one embodiment of the first, second, third, fifth, sixth, eighth and ninth aspects, the immune cell is a T-lymphocyte.

In one embodiment the first, second, third, fifth, sixth, eighth and ninth aspects, the immune cell is a CD8+ T-lymphocyte.

In one embodiment the first, second, third, fifth, sixth, eighth and ninth aspects, the immune cell is a cytotoxic CD8+ T-lymphocyte.

In one embodiment of the above aspects, the antigen is a viral antigen.

In one embodiment of the above aspects, the antigen is a human immunodeficiency virus antigen.

In one embodiment of the above aspects, the antigen is a human immunodeficiency virus antigen selected from a gpl20 env, gpl40 env, gpl60 env, p18, gag, pol, vif, vpr, vpu, tat, rev, and nef gene product, and combinations thereof.

In one embodiment of the above aspects, the antigen is a human immunodeficiency virus antigen selected from a gag, pol, or env gene product, or any combination thereof.

In one embodiment of the above aspects, the antigen is a human immunodeficiency virus antigen selected from a combined gag/pol, or a combined gag/pol/env gene product.
In one embodiment of the above aspects, the antigen and interleukin-4 receptor antagonist are administered to the subject sequentially.

In one embodiment of the above aspects, the antigen and interleukin-4 receptor antagonist are administered to the subject simultaneously.

In one embodiment of the above aspects, the antigen and interleukin-4 receptor antagonist are administered to the subject as a priming dose.

In one embodiment of the above aspects, the IL-4R antagonist is an interleukin-4 receptor alpha chain (IL-4Ra) antagonist capable of binding to IL-4Ra and preventing IL-4R signalling.

In one embodiment of the above aspects, the IL-4R antagonist is a human interleukin-4 molecule lacking a signal peptide and comprising one or more mutations selected from: a mutation at residue 121, a mutation at residue 124, a deletion of one or more residues after position 123, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

In a tenth aspect, the present invention provides a composition comprising:

(i) an antigen and/or a polynucleotide encoding the antigen; and

(ii) an interleukin-4 receptor (IL-4R) antagonist and/or a polynucleotide encoding the IL-4R antagonist.

In an eleventh aspect, the present invention provides the use of an antigen and an interleukin-4 receptor (IL-4R) antagonist in the manufacture of a medicament for preventing or treating an infection in a subject.

In a twelfth aspect, the present invention provides the use of an antigen and an interleukin-4 receptor (IL-4R) antagonist in the manufacture of a medicament for vaccinating a subject against an infection.

In a thirteenth aspect, the present invention provides an antigen and an interleukin-4 receptor (IL-4R) antagonist for use in preventing or treating an infection in a subject.

In a fourteenth aspect, the present invention provides the use of an antigen and an interleukin-4 receptor (IL-4R) antagonist for use in vaccinating a subject against an infection.

In one embodiment of the eleventh aspect the medicament is a vaccine.

In one embodiment of the thirteenth aspect the antigen and interleukin-4 receptor (IL-4R) antagonist are components of a vaccine.

In one embodiment of the eleventh and thirteenth aspects, the vaccine comprises first and second components, wherein the first component comprises the interleukin-4 receptor (IL-4R) antagonist and the second component comprises the antigen, and
wherein the first and second components are for, or are formulated for, simultaneous or sequential administration to the subject.

In one embodiment of the eleventh and thirteenth aspects, the vaccine is formulated for, or are formulated for, simultaneous or sequential administration to a subject, as a primer dose, a booster dose, or both.

In one embodiment of the twelfth aspect, the medicament is formulated for, or are formulated for, simultaneous or sequential administration to the subject, as a primer dose, a booster dose, or both.

In one embodiment of the fourteenth aspect, the antigen and interleukin-4 receptor (IL-4R) antagonist is formulated for, or are formulated for, simultaneous or sequential administration to the subject, as a primer dose, a booster dose, or both.

In one embodiment of the eleventh and thirteenth aspects, the vaccine is capable of decreasing the number of CD103+, b220+, CD8α+ cells in the subject and/or increasing CD103-, b220-, CD8α- cells in the subject, upon administration to the subject. The CD103+, b220+, CD8α+ cells and/or CD103-, b220-, CD8α- cells may be specific for the antigen. The antigen may be an HIV antigen (e.g. HIV gag, pol and/or env antigen).

In one embodiment of the twelfth and fourteenth aspects, said vaccinating is capable of decreasing the number of CD103+, b220+, CD8α+ cells in the subject and/or increasing CD103-, b220-, CD8α- cells in the subject. The CD103+, b220+, CD8α+ cells and/or CD103-, b220-, CD8α- cells may be specific for the antigen. The antigen may be an HIV antigen (e.g. HIV gag, pol and/or env antigen).

In one embodiment of the eleventh, twelfth, thirteenth and fourteenth aspects, the antigen is provided as a polynucleotide encoding the antigen.

In one embodiment of the eleventh, twelfth, thirteenth and fourteenth aspects, the interleukin-4 receptor is provided as a polynucleotide encoding the interleukin-4 receptor antagonist.

In one embodiment of the tenth, eleventh, twelfth, thirteenth and fourteenth aspects, any one or more of said polynucleotides is a component of a recombinant virus.

In one embodiment of the tenth, eleventh, twelfth, thirteenth and fourteenth aspects, the recombinant virus is a poxvirus.

In one embodiment of the tenth, eleventh, twelfth, thirteenth and fourteenth aspects, the recombinant virus is a poxvirus selected from the group consisting of a vaccinia virus, an attenuated vaccinia virus (e.g. NYVAC), a fowlpox virus, a canarypox virus, and a modified vaccinia ankara virus.
In one embodiment of the eleventh, twelfth, thirteenth and fourteenth aspects, the recombinant virus transiently expresses the interleukin-4 receptor (IL-4R) antagonist in the subject.

In one embodiment of the tenth, eleventh, twelfth, thirteenth and fourteenth aspects, the antigen is a viral antigen.

In one embodiment of the tenth, eleventh, twelfth, thirteenth and fourteenth aspects, the antigen is a human immunodeficiency virus antigen selected from a gag, pol, or env gene product, or any combination thereof.

In one embodiment of the tenth, eleventh, twelfth, thirteenth and fourteenth aspects, the antigen is a human immunodeficiency virus antigen selected from a combined gag/pol, or a combined gag/pol/env gene product.

In one embodiment of the tenth, eleventh, twelfth, thirteenth and fourteenth aspects, the IL-4R antagonist is an interleukin-4 receptor alpha chain (IL-4Ra) antagonist capable of binding to IL-Ra and preventing IL-4R signalling.

In one embodiment of the tenth, eleventh, twelfth, thirteenth and fourteenth aspects, the IL-4R antagonist is a human interleukin-4 molecule lacking a signal peptide and comprising one or more mutations selected from: a mutation at residue 121, a mutation at residue 124, a deletion of one or more residues after position 123, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

In one embodiment of the tenth, eleventh, twelfth, thirteenth and fourteenth aspects, the mutation is selected from: R121D, Y124D, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

In a fifteenth aspect, the present invention provides a method for preventing or treating an infection in a subject, the method comprising administering to the subject the composition according to the tenth aspect.

In a sixteenth aspect, the present invention provides a method of vaccinating a subject against an infection, the method comprising administering a primer dose and a booster dose of the composition according to the tenth aspect.

In one embodiment of the fifteenth and sixteenth aspects, the infection is human immunodeficiency virus infection and the composition comprises a human
immunodeficiency virus antigen selected from a gag, pol, or env gene product, or any combination thereof.

In one embodiment of the eleventh, twelfth, thirteenth, and fourteenth aspects, the infection is human immunodeficiency virus infection and the antigen is a human immunodeficiency virus antigen selected from a gag, pol, or env gene product, or any combination thereof.

**Brief Description of the Figures**

Preferred embodiments of the present invention will now be described, by way of example only, with reference to the accompanying figures wherein:

**Figure 1** shows the MVA del-III synthetic vector sequence comprising an intergenic insertion site created between MVA164 and MVA165 including sequences from Fsel to HindIII sites, and incorporating a fowlpox virus early/late promoter.

**Figure 2** shows the MVA "HindIII F" insertion site, wherein a multiple cloning site containing Fsel to HindIII (including an upstream T5NT early transcription termination signal) has been inserted between ORFs F8L and F7L.

**Figure 3** shows a synthetic SIV mac239 gag/pol sequence optimised for expression in macaque monkeys. The sequence contains a synthetic poxvirus early/late promoter upstream of the genes and an early transcription terminator sequence (T5NT) downstream flanked by restriction endonuclease site to facilitate cloning. The genes are expressed as a fusion protein resulting from a frame-shift during translation in the overlapping region.

**Figure 4** is a timecourse graph showing HIV KdGag-specific CD8+ T-cell avidity following co-vaccination with IL-4 receptor (IL-4R) antagonist (IL-4C1 18). FPV HIV IL-4C1 18/VV HIV IL-4C1 18 = priming vaccination with recombinant fowlpox virus encoding HIV gag/pol antigen and mutant IL-4C1 18 followed by booster vaccine with recombinant vaccinia virus encoding HIV gag/pol antigen and mutant IL-4C1 18. FPV HIV/VV HIV = primer vaccination with recombinant fowlpox encoding HIV gag/pol (no IL-4 receptor antagonist) followed by booster vaccination with recombinant vaccinia virus encoding HIV gag/pol (no IL-4 receptor antagonist).

**Figure 5** is a column graph showing HIV KdGag-specific CD8+ T-cell avidity and magnitude of HIV KdGag-specific CD8+ T-cell responses following co-vaccination with IL-4 receptor antagonist. FPV HIV/VV HIV = priming vaccination with recombinant fowlpox encoding HIV gag/pol (no IL-4 receptor antagonist) followed by booster vaccination with recombinant vaccinia virus encoding HIV gag/pol (no IL-4 receptor antagonist).
antagonist); FPV HIV IL-4C1 18/VV HIV = priming vaccination with recombinant fowlpox virus encoding HIV gag/pol antigen and mutant IL-4C1 18 followed by booster vaccine with recombinant vaccinia virus encoding HIV gag/pol (no IL-4 receptor antagonist); FPV HIV/VV HIV IL-4C1 18 = priming vaccination with recombinant vaccinia virus encoding HIV gag/pol antigen and mutant IL-4C1 18 followed by booster vaccine with recombinant fowlpox virus encoding HIV gag/pol (no IL-4 receptor antagonist); FPV HIV IL-4CU8/VV HIV IL-4CU8 = priming vaccination with recombinant fowlpox virus encoding HIV gag/pol antigen and mutant IL-4C1 18 followed by booster vaccine with recombinant vaccinia virus encoding HIV gag/pol antigen and mutant IL-4C1 18.

**Figure 6** is a column graph showing HIVKdGag-specific systemic (spleen) CD8⁺ T-cell immunity following co-vaccination with IL-4 receptor antagonist. Grey column = priming and booster vaccinations using recombinant viral vaccine encoding IL-4 receptor antagonist (IL-4C1 18) and HIV gag/pol antigens. Black column - priming and booster vaccinations using recombinant viral vaccine encoding HIV gag/pol antigens only (no IL-4 receptor antagonist).

**Figure 7** is a column graph showing HIV KdGag-specific mucosal (genito-rectal nodes) CD8⁺ T-cell immunity following IL-4 receptor antagonist (IL-4C1 18) prime-boost vaccination. FPV HIV IL-4C1 18/VV HIV IL-4C1 18 = priming vaccination with recombinant fowlpox virus encoding HIV gag/pol antigen and mutant IL-4C1 18; FPV HIV/VV HIV = priming vaccination with recombinant fowlpox encoding HIV gag/pol (no IL-4 receptor antagonist) followed by booster vaccination with recombinant vaccinia virus encoding HIV gag/pol (no IL-4 receptor antagonist);

**Figure 8** provides two graphs indicating the level of protective immunity following mucosal influenza-KdGag challenge in the presence or absence of IL-4 receptor antagonist or interleukin 13 (IL-13) receptor antagonists, as assessed by weight loss and CD8⁺ T-cell responses. FPV HIV IL-4C1 18/VV HIV IL-4C1 18 = priming vaccination with recombinant fowlpox virus encoding HIV gag/pol antigen and mutant IL-4C1 18 followed by booster vaccine with recombinant vaccinia virus encoding HIV gag/pol antigen and mutant IL-4C1 18; FPV HIV/VV HIV = priming vaccination with recombinant fowlpox encoding HIV gag/pol (no IL-4 receptor antagonist) followed by booster vaccination with recombinant vaccinia virus encoding HIV gag/pol (no IL-4 receptor antagonist); FPV HIVA10/VV HIVA10 = priming vaccination with recombinant fowlpox virus encoding HIV gag/pol antigen and IL-13Ra2 soluble receptor followed by
booster vaccination with recombinant vaccinia virus encoding HIV gag/pol antigen and IL-13Ra2 soluble receptor; FPV HIV/VV HIV (IL 13 -/-) = priming vaccination with recombinant fowlpox encoding HIV gag/pol (no IL-4 receptor antagonist) followed by booster vaccination with recombinant vaccinia virus encoding HIV gag/pol (no IL-4 receptor antagonist) in IL-13 knockout mice; (n = 6-14 per group; error bar = SEM).

Figure 9 provides two graphs showing memory systemic and mucosal HIV-specific T cell responses measured by ELISpot at 8 weeks post booster immunisation. FPV HIV/VV HIV = priming vaccination with recombinant fowlpox encoding HIV gag/pol (no IL-4 receptor antagonist) followed by booster vaccination with recombinant vaccinia virus encoding HIV gag/pol (no IL-4 receptor antagonist); FPV HIV IL-4C1 18/VV HIV IL-4C1 18 = priming vaccination with recombinant fowlpox virus encoding HIV gag/pol antigen and mutant IL-4C1 18 followed by booster vaccine with recombinant vaccinia virus encoding HIV gag/pol antigen and mutant IL-4C1 18.

Figure 10 provides a series of dotplots setting out an antigen presenting cell (APC) subset gating strategy used in the evaluation of APC subsets in the lung mucosae 24 hours post-priming vaccination. R1 = total APC subsets; R2 = forward scatter (FSC) doublet discrimination; R3 = side scatter (SSC) doublet discrimination; R5 = cells gated on MHC 11+ CD1 lc+ = APC subset; APC = antigen presenting cell; DC = dendritic cell; CD1 lc = DC marker; 1A4d = MHC II cell marker.

Figure 11 provides a series of dotplots evaluating CD103 associated antigen presenting cell subsets in the lung mucosae 24h post priming vaccination. FPV-HIV = Fowl pox virus expressing HIV gag/pol genes or Fowl pox virus expressing HIV gag/pol/env genes; VV-HIV = Vaccinia virus expressing HIV gag/pol genes; MVA-HIV = Modified vaccinia ankara expressing HIV gag/pol genes; FPV-HIV IL-13KO = IL-13 knockout animals given the control vaccine FPV-HIV; FPV-HIV IL-13Ra2 = Fowl pox virus co-expressing HIV gag/pol genes and soluble IL-13Ra2 or Fowl pox virus co-expressing HIV gag/pol/ env genes and soluble IL-13Ra2; FPV-HIV C118 = Fowl pox virus co-expressing HIV gag/pol genes and IL-4 antagonist or Fowl pox virus expressing HIV gag/pol/env genes and IL-4 antagonist; CD1 lb = dendritic cell marker; CD103 = lung/skin-specific T cell marker; IL-13KO= IL-13/- gene knockout mice.

Figure 12 provides a series of dotplots evaluating B220 associated antigen presenting cell subsets in the lung mucosae 24h post priming vaccination. FPV-HIV = Fowl pox virus expressing HIV gag/pol genes or Fowl pox virus expressing HIV gag/pol/env genes; VV-HIV = Vaccinia virus expressing HIV gag/pol genes; MVA-HIV = Modified vaccinia ankara expressing HIV gag/pol genes; FPV-HIV IL-13KO = IL-13
knockout animals given the control vaccine FPV-HIV; FPV-HIV IL-13Rcc2 = Fowl pox virus co-expressing HIV gag/pol genes and soluble IL-13Ra2 or Fowl pox virus co-expressing HIVgag/pol/ env genes and soluble IL-13Ra2; FPV-HIV C118 = Fowl pox virus co-expressing HIV gag/pol genes and IL-4 antagonist or Fowl pox virus expressing HIV gag/pol/env genes and IL-4 antagonist; VV-IL13KO = IL-13 knockout animals given the control vaccine VV-HIV; VV-HIV IL-13Ra2 = Vaccinia virus co-expressing HIV gag/pol genes and soluble IL-13Ra2; CD11b = dendritic cell marker; B220 = B cell marker; C118 = IL-4 antagonist.

Figure 13 provides a series of dotplots evaluating CD8-associated antigen presenting cell subsets in the lung mucosae 24h post priming vaccination. FPV-HIV = Fowl pox virus expressing HIV gag/pol genes or Fowl pox virus expressing HIV gag/pol/env genes; VV-HIV = Vaccinia virus expressing HIV gag/pol genes; MVA-HIV = Modified vaccinia ankara expressing HIV gag/pol genes; FPV-HIV IL-13KO = IL-13 knockout animals given the control vaccine FPV-HIV; FPV-HIV IL-13Roc2 = Fowl pox virus co-expressing HIV gag/pol genes and soluble IL-13Ra2 or Fowl pox virus co-expressing HIVgag/pol/ env genes and soluble IL-13Ra2; FPV-HIV C118 = Fowl pox virus co-expressing HIV gag/pol genes and IL-4 antagonist or Fowl pox virus expressing HIV gag/pol/env genes and IL-4 antagonist. CD11b = dendritic cell marker; CD8a = dendritic cell marker.

Figure 14 is a column graph demonstrating that serum IgGl responses to p24Gag are enhanced following HIV-IL-4R antagonist adjuvanted vaccination.

Definitions

As used in this application, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the phrase "virus" also includes a plurality of viruses.

As used herein, the term "comprising" means "including." Variations of the word "comprising", such as "comprise" and "comprises," have correspondingly varied meanings. Thus, for example, a vaccine "comprising" a recombinant virus may consist exclusively of that recombinant virus or may include one or more additional components (e.g. additional type(s) of recombinant viruses).

As used herein, the "therapeutically effective amount" includes within its meaning a non-toxic but sufficient amount of an agent or composition for use in the present invention to provide the desired therapeutic effect. The exact amount required will vary
from subject to subject depending on factors such as the species being treated, the age and
general condition of the subject, the severity of the condition being treated, the particular
agent being administered, the mode of administration and so forth. Thus, it is not
possible to specify an exact "effective amount" applicable to all embodiments. However,
for any given case, an appropriate "effective amount" may be determined by one of
ordinary skill in the art using only routine experimentation.

As used herein, the term "subject" includes any animal of economic, social or
research importance including bovine, equine, ovine, primate, avian and rodent species.
Hence, a "subject" may be a mammal such as, for example, a human or a non-human
mammal.

As used herein, the term "IL-4 antagonist" encompasses any agent capable of
preventing or inhibiting the production and/or biological function of IL-4 including, for
example, IL-4 receptor (IL-4R) and IL-4 receptor alpha chain (IL-4Ra) antagonists.

As used herein, the terms "antagonist of IL-4R", "IL-4R antagonist", and
"interleukin-4 receptor antagonist" are used interchangeably and have the same meaning.
The terms encompass any agent capable of preventing or inhibiting the activation and/or
continuation of a cell signaling pathway that is initiated by (i.e. commences directly via)
IL-4Ra or a receptor complex comprising IL-4Rα. In some embodiments an IL-4R
antagonist may be an agent that binds to IL-4Ra without initiating IL-4Ra-mediated cell
signaling and thereby preventing or altering a binding interaction between IL-4Ra and
one or more ligands (e.g. IL-4 and/or IL-13) that may otherwise be capable of activating
the IL-4R receptor complex in the absence of the antagonist. In other embodiments an IL-
4R antagonist may be an agent that binds to one or more ligands of IL-4Ra (e.g. IL-4
and/or IL-13) thereby blocking or altering a binding interaction between the ligand and
IL-4Ra. In other embodiments, an IL-4R antagonist may be an agent capable of
inhibiting or blocking a cell signaling pathway that has been initiated by (i.e. commences
via) IL-4Roc or a receptor complex comprising IL-4Roc. For example, the agent may
interact with or modify the activity of a downstream protein or molecule in a signaling
pathway that is initiated by (i.e. commences via) IL-4Ra or a receptor complex
comprising IL-4Roc.

As used herein, the term "avidity" in the context of an immune cell/immune cell
population and a given antigen means the quantity or concentration of the antigen
required to elicit an antigen-specific response in the immune cell/immune cell population.

As used herein, the terms "antibody" and "antibodies" include IgG (including IgGl,
IgG2, IgG3, and IgG4), IgA (including IgAl and IgA2), IgD, IgE, or IgM, and IgY,
whole antibodies, including single-chain whole antibodies, and antigen-binding fragments thereof. Antigen-binding antibody fragments include, but are not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. The antibodies may be from any animal origin. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entire or partial of the following: hinge region, CH1, CH2, and CH3 domains. Also included are any combinations of variable region(s) and hinge region, CH1, CH2, and CH3 domains. Antibodies may be monoclonal, polyclonal, chimeric, multispecific, humanized, and human monoclonal and polyclonal antibodies which specifically bind the biological molecule.

As used herein, the terms "protein", "polypeptide" and "peptide" each refer to a polymer made up of amino acids linked together by peptide bonds and are used interchangeably. For the purposes of the present invention a "polypeptide" may constitute a full length protein or a portion of a full length protein.

As used herein, the term "polynucleotide" refers to a single- or double-stranded polymer of deoxyribonucleotide bases, ribonucleotide bases, known analogues of natural nucleotides, and mixtures thereof.

As used herein, the term "nucleotide sequence" will be understood to encompass DNA sequences, RNA sequences, and complementary (cDNA) sequences.

As used herein, the term "parent virus" will be understood to be a reference to a virus that can be modified to incorporate exogenous genetic material to form a recombinant virus of the present invention.

As used herein, the term "recombinant virus" will be understood to be a reference to a "parent virus" comprising at least one exogenous nucleotide sequence.

As used herein, the term "exogenous nucleotide sequence" when used in the context of a recombinant virus will be understood to encompass any nucleotide sequence inserted into the genome of a parent virus to form a recombinant virus.

As used herein, the term "immunogenic" when used in the context of a given component such as, for example, a nucleotide sequence, polypeptide, an exogenous nucleotide sequence, an exogenous polypeptide, an antigen, or an epitope, means that the agent has a capability to induce an immune response, enhance an existing immune response, or alter an existing immune response, either alone, or acting in combination with other agent(s).
It will be understood that "inducing" an immune response as contemplated herein includes inciting an immune response and enhancing a previously existing immune response.

As used herein, the term "kit" refers to any delivery system for delivering materials. Such delivery systems include systems that allow for the storage, transport, or delivery of reaction reagents (for example labels, reference samples, supporting material, etc. in the appropriate containers) and/or supporting materials (for example, buffers, written instructions for performing an assay etc.) from one location to another. For example, kits may include one or more enclosures, such as boxes, containing the relevant reaction reagents and/or supporting materials. The term "kit" includes both fragmented and combined kits.

As used herein, the term "fragmented kit" refers to a delivery system comprising two or more separate containers that each contains a subportion of the total kit components. The containers may be delivered to the intended recipient together or separately. Any delivery system comprising two or more separate containers that each contains a subportion of the total kit components are included within the meaning of the term "fragmented kit".

As used herein, a "combined kit" refers to a delivery system containing all of the components of a reaction assay in a single container (e.g. in a single box housing each of the desired components).

It will be understood that use the term "about" herein in reference to a recited numerical value includes the recited numerical value and numerical values within plus or minus ten percent of the recited value.

It will be understood that use of the term "between" herein when referring to a range of numerical values encompasses the numerical values at each endpoint of the range. For example, a polypeptide of between 10 residues and 20 residues in length is inclusive of a polypeptide of 10 residues in length and a polypeptide of 20 residues in length.

Any description of prior art documents herein, or statements herein derived from or based on those documents, is not an admission that the documents or derived statements are part of the common general knowledge of the relevant art.

For the purposes of description all documents referred to herein are hereby incorporated by reference in their entirety unless otherwise stated.
Detailed Description

The following detailed description conveys exemplary embodiments of the present invention in sufficient detail to enable those of ordinary skill in the art to practice the present invention. Features or limitations of the various embodiments described do not necessarily limit other embodiments of the present invention or the present invention as a whole. Hence, the following detailed description does not limit the scope of the present invention, which is defined only by the claims.

Vaccines capable of eliciting high-avidity T-lymphocyte responses and/or a sizeable magnitude of T lymphocyte responses against viral antigens are highly sought after in the field. Given that mucosal surfaces are the first portals of entry for viruses, vaccines capable of eliciting responses at these sites are also desirable. The present inventors have identified that the avidity and/or magnitude of antigen-specific T-lymphocyte responses can be significantly enhanced by inhibiting IL-4, that is, by reducing the availability of IL-4 and/or inhibiting IL-4 function. This may be done transiently, such that normal IL-4 levels and function can be restored in the long term.

Accordingly, some aspects of the present invention relate to compositions, vaccines and medicaments capable of enhancing the magnitude of immune cell responses and/or enhancing immune cell avidity for a targeted infectious agent. The compositions may comprise an immunogenic component capable of inducing immunity against the infectious agent together with a component capable of inhibiting the production and/or activity of IL-4. Alternatively, the immunogenic component and component capable of inhibiting the production and/or activity of IL-4 may be provided in separate compositions for simultaneous or sequential administration. Compositions of the present invention may be provided in kits.

Other aspects of the present relation relate to methods for inducing antigen-specific immune responses in a subject. The methods comprise administering one or more compositions of the invention, and may be effective in increasing the avidity of immune cells for the antigen in a subject and/or increasing the number of immune cells specific for the antigen.

Still other aspects of the present invention relate to methods for preventing and/or treating infection by administration of the compositions, vaccines and medicaments provided herein. The methods may involve administration of preventative and/or therapeutic vaccines.
Interleukin-4 (IL-4) antagonists

As known to those skilled in the field, IL-4 is an immunoregulatory cytokine capable of binding two separate receptor complexes. The type I receptor complex comprises the interleukin-4 receptor alpha (IL-4Ret) chain and the common gamma chain (yc). The type II receptor complex comprises the IL-4Ra chain but the yc is substituted by the IL-13 protein receptor alpha 1 (IL-13Ral) chain or the IL-13 protein receptor 2 (IL-13Ra2) chain. In either case, only the IL-4Ra chain is capable of binding IL-4, and heterodimerisation of the IL-4Ra chain with yc, IL-13Ral, or IL-13Ra2 is also required to initiate cell signalling (via the JAK/STAT pathway in the case of IL-4Ra/yc and IL-4Ro/IL-13Ral).

The compositions and methods of the present invention employ antagonists of IL-4 production and/or function. As demonstrated in the Examples of the present specification, the IL-4 antagonists have been found to significantly increase/enhance the magnitude and/or avidity of immune cell responses for a co-administered antigen. Without being limited by theory, it is postulated that inhibition of IL-4 production and/or function in the local milieu of an immune response reduces inhibitory effects on antigen-specific CTL production and/or function. Accordingly, when co-administered with a particular antigen the IL-4 antagonists provide a greater magnitude and/or avidity of antigen-specific cells (e.g. antigen specific CD8+ T lymphocytes).

An IL-4 antagonist as contemplated herein encompasses any agent capable of preventing or inhibiting the production and/or biological function of IL-4. Given that many of the biological functions of IL-4 are mediated through binding interactions with IL-4R, many antagonists of IL-4 production and/or function are also antagonists of IL-4R (and vice versa).

The IL-4 antagonist may inhibit the production and/or biological function of IL-4 by virtue of a binding interaction with IL-4. The binding interaction between the antagonist and IL-4 may prevent IL-4 from binding to or otherwise interacting with other molecule(s) (e.g. IL-4Ra) and thereby inhibit IL-4 function and/or production. In this case, the affinity of the binding interaction between IL-4 and the antagonist may be higher than that of the binding interaction between IL-4 and the other molecule(s) to which it may otherwise bind. By way of non-limiting example only, soluble forms of the IL-4 receptor may be used as IL-4 antagonists. These may be mutated so as to bind to IL-4 with high affinity (e.g. a soluble IL-4R exclusively composed of the extracellular domain of the IL-4Ra chain). Antibodies may also be used as IL-4 antagonists. The antibodies may have binding specificity the IL-4R (e.g. IL-4Ra), or, a ligand of IL-4Ra (e.g. IL-4).
Additionally or alternatively, the IL-4 antagonist may inhibit the production and/or biological function of IL-4 by preventing or inhibiting the expression and/or function of any one or more downstream proteins or molecules in a signaling pathway that is initiated by (i.e. commences via) IL-4R. For example, the agent may interact with or modify the activity of a downstream protein or molecule in a signaling pathway that is initiated by (i.e. commences via) IL-4R or a receptor complex comprising IL-4Ra.

Additionally or alternatively, the IL-4 antagonist may inhibit the production and/or biological function of IL-4 by virtue of a binding interaction with the IL-4R or a component thereof (e.g. IL-4Ra). In this case, the binding interaction will generally not initiate cell signalling mediated through IL-4R, but the binding affinity will generally be sufficient to prevent other ligands binding to the IL-4R or component thereof (e.g. IL-4Ra), or the capacity to bind in a manner that is capable of initiating cell signalling via IL-4R.

By way of non-limiting example, the IL-4 antagonist may be one which binds to IL-4R or a component thereof (e.g. IL-4Ra). These IL-4 antagonists are therefore also IL-4R antagonists and IL-4Ra antagonists. The binding interaction generally does not induce significant levels of cell signalling, or, induce any cell signalling, via the IL-4R, but the affinity of the interaction is of sufficient strength to prevent other ligands of the IL-4R (e.g. IL-4 and/or IL-13) from either binding to the IL-4R (e.g. to IL-4Roc), or the capacity to bind in a manner that is capable of initiating cell signalling via IL-4R.

In certain embodiments, the IL-4 antagonist binds to IL-4Ra (and is thus also an antagonist of IL-4Roc). Any IL-4 antagonist that binds to IL-4Ra without substantially instigating cell signalling, whilst preventing interactions between IL-4Ra (or an IL-4 comprising IL-4Ra) and a ligand thereof may be used in compositions and methods of the present invention. Antagonists of this category are well known to persons skilled in the field and include, for example, modified ligands of IL-4Ra (e.g. mutant IL-4 molecules) that are capable of binding to IL-4Ra without initiating cell signalling, thus blocking IL-4R function. Specific and non-limiting examples of modified IL-4Rcc ligands include IL-4 with C-terminal mutations such as the deletion of one or more C terminus residues (e.g. deletion or substitution of tyrosine residue 119 in the secreted form of murine IL-4 such as IL-4C1 18 as described herein) and equivalent mutations in other mammalian IL-4 homologues; deletion or substitution of tyrosine at position 124 in the secreted form of human or macaque IL-4 (e.g. IL-4C123 as described herein) and equivalent mutations in other mammalian IL-4 homologues; splice variants such as those with a deletion of residue(s) encoded by exon 2 of the IL-4 gene (e.g. IL-4 delta 2 in humans and equivalent
mutations in other mammalian IL-4 homologues); and mutations at positions 121 and/or 124 in the mature secreted form of the human IL-4 protein and equivalent positions in other mammalian IL-4 homologues (e.g. the IL-4 Y124D mutant or the R121D/Y124D IL-4 mutant in humans; the Q16D/Y19D IL-4 mutant or the Y19D mutant in mice). It is also contemplated that IL-4Ra-specific antibodies could also be designed to bind to IL-4Rα without substantially instigating cell signalling.

Numerous methods are available to determine IL-4R binding interactions and/or IL-4R-mediated cell signaling, and are well known to those in the field. Non-limiting examples include surface plasmon resonance, fluorescence resonance energy transfer (TR-FRET), chemical co-immunoprecipitation, bioluminescence resonance energy transfer (BRET), IL-4-dependent STAT6 activation measured by electrophoretic mobility shift assay (EMSA), and the like.

**Antigens**

The compositions and methods of the present invention employ antigens for stimulating immune responses. The antigen-specific immune response induced is enhanced by the presence of an IL-4 antagonist (e.g. an IL-4Ra antagonist).

The antigen may be any molecule capable of stimulating an immune response in a subject (e.g. proteins, peptides, polysaccharides and the like), including endogenous (self) antigens and exogenous (foreign) antigens. Combinations of antigens may be utilised.

In certain embodiments, the antigen is a peptide antigen. The peptide antigen may be of a size that is suitable for stimulating an immune response to the target antigen of interest. The size of the peptide used may be optimised for T cell and/or B cell epitope processing requirements. Those of skill in the field will recognise that major histocompatibility complex class I-restricted T cell epitopes are generally between 8 and 10 amino acid residues long, whereas class II-restricted T cell epitopes are generally between 12 and 25 amino acid residues long. Flanking residues may be included in either case for optimal proteolytic processing (e.g. 2-3 natural flanking amino acid residues for a class I-restricted T cell epitope). Class II-restricted epitopes may contain a central 9-10 amino acid residue core that binds specifically to class II MHC molecules, with flanking residues on either side of the core serving to stabilise binding.

A linear B cell epitope may be at least: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or 30 amino acid residues. The size of the B cell epitope may be less than about: 500, 200, 100, 80, 60, 50, or 40 amino acid residues in length.
The size of the peptide used in a composition or method of the present invention may be suitable for presentation of an epitope contained within the peptide by an antigen-presenting cell to a T lymphocyte and/or a B lymphocyte.

Techniques for identifying and selecting effective antigenic peptides (e.g. minimal peptide sequences capable of eliciting an immune response) are well known to those skilled in the field. By way of non-limiting example only, reference is made to Rappuoli and Bagnoli (Eds), (2011), "Vaccine Design: Innovative Approaches and Novel Strategies", Caister Academic Press, UK; and Agudelo and Patarroyo, (2010), "Quantum chemical analysis of MHC-peptide interactions for vaccine design", Mini Rev Med Chem; 10(8):746-58, the entire contents of which are incorporated herein by reference.

In some embodiments, the antigens may be viral antigens. Exemplary viral components from which the antigens may be derived include envelopes, coats, capsules, capsids, toxins, RNA, DNA and combinations thereof. No particular limitation exists in relation to the particular type of virus from which the antigen may be derived. Non-limiting examples include herpesviruses (e.g. human herpesvirus (HHV) types 1-8) such as herpes simplex virus types I and II, cytomegalovirus, varicella zoster virus, epstein banvirus; hepatitis viruses (e.g. hepatitis A, B, C); orthomyxoviruses (e.g. influenza virus types A, B, C and recombinant forms thereof); flaviviruses (e.g. dengue virus, west nile virus, Japanese encephalitis virus, yellow fever virus); coronaviruses (e.g. SARS virus); paramyxoviruses (e.g. hendra virus, measles virus, sendai virus, mumps virus, respiratory syncitial virus); enteroviruses (e.g. coxsackieviruses, polioviruses, rhinoviruses); togaviruses (e.g. rubellavirus); adenoviruses (e.g. types 4 and 7); papillomaviruses (e.g. human papillomavirus); filoviruses (e.g. ebola virus); bunyaviruses (e.g. hantavirus, phlebovirus); rhabdoviruses (e.g. vesicular stomatitis virus; lyssaviruses such as the rabies virus); and retroviruses (e.g. lentiviruses such as HIV-1, HIV-2, SIV and visna virus).

Any suitable antigen from a given virus may be used. Non-limiting examples of herpes simplex viral antigens include immediate early proteins, glycoprotein B, glycoprotein D and VZV antigens 9PI and gpll. Non-limiting examples of antigens from hepatitis viruses include the S, M, and L envelope proteins and pre-S surface antigen. Non-limiting examples of suitable influenza virus antigens include haemagglutinin, neuraminidase and other influenza virus envelope proteins. Non-limiting examples of Japanese encephalitis viral antigens include proteins E, M-E, M-E-NS 1, NS 1, and NS 1-NS2A. Non-limiting examples of measles virus antigens include the measles virus fusion protein. Exemplary antigens of the rubella virus include, but are not limited to, proteins El
and E2. Exemplary rotaviral antigens included VP7sc. Non-limiting examples of respiratory syncytial viral antigens include the RSV fusion protein and the M2 protein. Exemplary rabies virus antigens include, but are not limited to, the rabies virus glycoprotein and the rabies virus nucleoprotein. Non-limiting examples of papillomavirus antigens include the L1 and L2 capsid proteins and the E6/E7 antigens associated with cervical cancers.

In certain embodiments, the viral antigen is from a retrovirus. The retrovirus may be a human immunodeficiency virus (e.g. HIV-1 or HIV-2). Non-limiting examples of suitable antigens from HIV include those in gene products of the gpl20 env, gpl40 env, gpl60 env, p18, gag, pol, vif, vpr, vpu, tat, rev, and nef genes, and combinations thereof. For example, the antigen may be an HIV-1 gag, pol, env, gag/pol, or gag/pol/env gene product.

**Compositions**

Compositions of the present invention may comprise an immunogenic component (e.g. an antigen) capable of inducing immunity against a targeted agent together with a component capable of inhibiting the production and/or activity of IL-4.

Alternatively, the immunogenic component (e.g. antigen) and component capable of inhibiting the production and/or activity of IL-4 may be provided in separate compositions formulated for simultaneous or sequential administration.

**Polypeptides and proteins**

Compositions of the present invention may comprise an IL-4 antagonist (e.g. an IL-4Rct antagonist) and/or an immunogenic component (e.g. an antigen) capable of inducing immunity against a targeted agent.

The compositions may be formulated for injection, inhalation or topical administration facilitating direct exposure of host cells and tissues to the antagonist and/or immunogenic component. In certain embodiments, the antagonist and/or immunogenic component may be provided in nanoparticles (see, for example, methodologies described in US patent nos. 7,611,690, 7,858,596, and 8,048,404). Additionally or alternatively, the compositions may be formulated in dry powder form suitable for delivery by particle bombardment (see, for example, methods relying on gas-driven particle acceleration such as those described in US patent nos. 5,584,807, 5,865,796, and 6,010,478; and methods relying on gas-driven needleless injection such as those described in US patent nos. 5,299,163, 5,383,851 and 5,993,412).
- nucleic acid constructs

Compositions of the present invention may comprise nucleic acid constructs capable of expressing polynucleotide(s) encoding an IL-4 antagonist and/or an immunogenic component (e.g. an antigen) capable of inducing immunity against a targeted agent. The polynucleotide encoding the IL-4 antagonist may be in the same or a different construct to the polynucleotide encoding the immunogenic component. The nucleic acid construct may be, for example, an expression vector, a plasmid vector, a viral vector, a phosmid, a cosmid, a recombinant virus or any other vector construct suitable for the insertion of foreign sequences, introduction into cells and subsequent expression of the introduced sequences.

The construct may be a replicon particle-based vaccine vector. Non-limiting examples include alphavirus replicon particle-based vaccine vectors derived from Sindbis virus (SIN), Semliki Forest virus (SFV), and Venezuelan equine encephalitis virus (VEE).

The polynucleotides encoding the IL-4 antagonist and/or immunogenic component (e.g. an antigen) may be operably linked to regulatory polynucleotide sequences (e.g. transcriptional and/or translational control sequences such as a promoter sequence, 5' untranslated region, 3' untranslated region, c/s-regulatory region, ribosomal-binding sequences, transcription and translation start sites, and the like). The promoters may be constitutive or inducible. The regulatory polynucleotide sequences may be compatible with for expression in the cell or tissue type for which the construct is intended for administration.

A promoter will be understood to mean a DNA sequence recognised by a cell's transcriptional machinery to initiate transcription of a downstream polynucleotide sequence. Non-limiting examples of suitable promoters include: constitutive promoters such as those found in some eukaryotic viruses such as the adenovirus, polyoma virus, CMV (e.g. cytomegalovirus immediate early gene promoter), SV40, Rous sarcoma virus (e.g. long terminal repeat promoter), avian sarcoma virus, herpes simplex virus thymidine kinase promoter, hepatitis B virus retroviral LTR regions; promoters present in eukaryotic genes such as: the EF-1 alpha promoter, metallothioneine gene promoter, actin promoter, and the immunoglobulin promoter; inducible promoters requiring the addition of a substance or an exogenous signal for expression such as the tetracycline promoter, NFKappaB/UV light, Cre/lox, heat shock promoters, regulatable RNA polymerase II promoters (see PCT publication No. WO/2006/135436); tissue-specific promoters such as the PSA promoter described in PCT publication No. WO/2006/012221; and constitutive RNA polymerase III promoters such as RNA pol III promoters from the 5S ARN, ARN -23-
7SL ARNt, ARNsn, H1 and U6 genes. Other non-limiting examples include the human
elongation factor 1α promoter, and the human ubiquitin c promoter.

The nucleic acid constructs may be formulated for delivery to target cells and
tissues using any suitable method known in the field.

In certain embodiments, the constructs may be formulated for delivery in the form
of naked DNA (see, for example, techniques described in US patent nos. 6,265,387,
6,972,013, and 7,922,709).

- recombinant viruses

In some embodiments, a nucleic acid construct included in a composition of the
present invention may be in the form of a recombinant virus. The virus may be
genetically modified to express a polynucleotide encoding one or more exogenous
proteins or exogenous protein components. For example, the recombinant virus may be
engineered so as to express a polynucleotide encoding an IL-4 antagonist (e.g. an IL-4Rcc
antagonist) and/or an immunogenic component comprising one or more antigens.

Recombinant viruses of the present invention may be produced by modification of a
"parent" virus to incorporate exogenous genetic material. Reference herein to a specific
type of recombinant virus (e.g. a recombinant fowlpox, vaccinia or poxvirus) denotes a
parent virus of the indicated type that has been modified to incorporate exogenous genetic
material.

No particular limitation exists regarding the specific type of parent virus used to
generate recombinant viruses of the present invention. Non-limiting examples of suitable
parent viruses include retroviruses (e.g. lentiviruses such as HIV, HIV-1, HIV-2, FIV,
BIV, EIAV, MW, CAEV, and SIV), adenoviruses and adeno-associated viruses,
alphaviruses (e.g. VEE), flaviviruses, and poxviruses (e.g. vaccinia viruses, avian pox
viruses (such as fowlpox virus), and avipox viruses).

The recombinant viruses may be live or live-attenuated recombinant viruses. In
general, the recombinant viruses are replication-competent meaning that they are capable
of reproducing in a host cell which they have infected.

Recombinant viruses of the present invention comprise at least one exogenous
nucleotide sequence. It will be understood that in the context of the present invention, a
nucleotide sequence encompasses DNA, RNA, and complementary (cDNA) sequences.

An exogenous nucleotide sequence as used herein encompasses any nucleotide
sequence inserted into the genome of a parent virus to form a recombinant virus. In
certain embodiments, the exogenous nucleotide sequence encodes an IL-4 antagonist (e.g.
an IL-4Ra antagonist) and/or an immunogenic molecule (e.g. an antigen) from a different microorganism (e.g. a different virus).

Without imposing any specific limitation on the length the exogenous nucleotide sequence, in some embodiments the sequence may be between about 10 to 15, 15 to 25, 20 to 30, 25 to 35, 30 to 40, 35 to 45, 40 to 50, 50 to 75, 75 to 100, 100 to 150, 150 to 200, 200 to 275, 275 to 350, 350 to 500, 500 to 750, 750 to 1000, 1000 to 1250, 1250 to 1500, 1500 to 1750, 1750 to 2000, 2000 to 2500, 2500 to 3000, or more than 3000 nucleotides in length.

A recombinant virus of the present invention may comprise multiple exogenous polynucleotide sequences, including duplicate(s) of the same exogenous sequence and/or combinations of different exogenous sequences (e.g. a polynucleotide encoding an IL-4 antagonist (e.g. an IL-4Rec antagonist) and a polynucleotide encoding an immunogenic component comprising one or more antigens.

No particular limitation exists regarding the location at which the exogenous polynucleotide sequence(s) is/are inserted into the virus genome, which will depend primarily on the particular polynucleotide(s) and the parent virus. However, it is preferred that the exogenous sequence is inserted at a location in the viral genome that minimises adverse effects on virus function, replication, and/or proteolytic processing of translated viral polypeptides.

An exogenous polynucleotide may be inserted into an open reading frame (ORF) of the virus. For example, the polynucleotide may be inserted at a junction between two viral genes. Alternatively, the polynucleotide may be inserted into the viral genome in a region that is not in an ORF. For example, the polynucleotide may be inserted into non-coding sequence between two different ORFs, 5' to an ORF (e.g. in the 5'-untranslated region (5'-UTR)), or 3' to an ORF (e.g. in the 3'-untranslated region (3'-UTR)).

An exogenous polynucleotide inserted into a parent virus may comprise at least one nucleotide sequence encoding a proteolytic cleavage site. The proteolytic cleavage site may be advantageous in facilitating cleavage and release of the encoded polypeptide from other viral-encoded polypeptides if translated as components of a single polypeptide. Suitable sequences encoding proteolytic cleavage sites and methods for their incorporation into other sequences are well known in the art and described in standard texts.

Recombinant viruses of the present invention may comprise at least one endogenous or exogenous nucleotide sequence for initiating translation of the exogenous
sequence (e.g. a 5’ cap, internal ribosome entry site, and the like) from the parent virus and/or from a different foreign virus.

An exogenous polynucleotide inserted into a parent virus may comprise a signal peptide for directing transport of an encoded IL-4 antagonist and/or immunogenic component (e.g. an antigen) within an infected cell (e.g. to the endoplasmic reticulum) and/or out of the infected cell.

Recombinant viruses according to the present invention may be generated using standard molecular biology techniques and recombinant nucleic acid technologies known to those skilled in the field. The particular method utilised will depend on the parent virus used and the particular exogenous polynucleotide(s) to be inserted. The insertion of exogenous nucleotide sequences into the parent virus can be accomplished using standard techniques of molecular biology. Suitable techniques are described, for example, in standard texts including Sambrook et al., (1989), “Molecular Cloning: A Laboratory Manual”, (2nd ed., Cold Spring Harbor Laboratory Press, Plainview, New York; and Ausubel et al. (Eds), (2000-2010), “Current Protocols in Molecular Biology”, John Wiley and Sons, Inc.. The Examples of the present specification also provide specific guidance on methods for the insertion of exogenous nucleotide sequences into a parent virus. Using these principles, any of a variety of exogenous nucleotide sequences may be inserted into a parent virus genome.

By way of non-limiting example only, genetic recombination may be used to transfer exogenous polynucleotides from a vector to a parent virus by homologous or heterologous recombination events. The exogenous polynucleotide may be provided in a vector flanked by sequence from the parent virus. The exogenous polynucleotide or flanking sequence may comprise a selectable marker. Upon infection of a host cell by the vector and parent virus, recombination events can serve to replace endogenous sequence of the parent virus with exogenous sequences from the vector. Recombinant viruses so generated may be selected using the selectable marker.

Additionally or alternatively, a recombinant viral complementary DNA (cDNA) construct may be generated comprising a cDNA copy of the parent virus genome with one or more exogenous cDNA sequences inserted at target position(s) in the genome. This may be achieved, for example, by generating cDNA fragments of the viral genome via polymerase chain reaction (PCR) and/or cloning plasmids comprising the fragments. Various genomic fragments may be joined together using, for example, appropriate restriction sites to cleave genomic cDNA fragments to produce, for example, overhanging ends that can be ligated to ends of other fragments. In this way, a cDNA copy of the viral
genome can be constructed with exogenous cDNA sequences inserted at desired position(s) along with an appropriately positioned promoter sequence for an RNA polymerase. An RNA copy of the recombinant cDNA construct may then be generated using an appropriate RNA polymerase. The viral RNA transcript may then be transfected into an appropriate cell line (e.g. BHK-21 cells or Vero cells) using an appropriate technique (e.g. electroporation), wherein production of recombinant viruses may then occur.

Additional non-limiting examples of suitable methodologies to prepare recombinant viruses from parent strains include retroviral systems such as those disclosed in US patent nos. 5,219,740, 5,219,740, 7,250,299 and 7,608,273, alphavirus systems such as those described in US patent nos. 6,465,634 and 7,811,812, flavivirus systems such as those described in US patent nos. 5,744,140 and 8,124,398, adeno-associated virus systems such as those described in US patent nos. 5,173,414, 7,022,519, and 7,125,705, adenovirus-based systems such as those described in US patent nos. 6,905,862, 7,989,425, and 6,468,771, poxvirus systems such as those described in US patent nos. 7,015,024 and 7,338,662, and avipox virus systems such as those described in US patent nos. 5,871,742 and 6,340,462.

- **exemplary recombinant viruses**

Certain embodiments of the present invention relate to compositions comprising recombinant poxviruses (i.e. poxviridae family), and in particular those of the Chordopoxvirinae subfamily of poxviruses. The use of such viruses may be advantageous in that their genomes can accommodate incorporation of large foreign DNA sequences. This in turn makes it possible to engineer these viruses to express heterologous gene sequences encoding full proteins (e.g. IL-4 antagonists including IL-4Ra receptor antagonists and/or immunogenic peptides comprising antigens). The use of these viruses may also be advantageous due to favourable safety profiles in animals including humans.

By way of non-limiting example only, attenuated vaccinia viruses, such as modified vaccinia virus Ankara (MVA), and NYVAC, may be used as parent strains to create recombinant poxviruses. The parent viruses may have had one or more pathogenic genes removed or inactivated during their generation.

Additionally or alternatively, host-restricted strains such as avipoxvirus vectors based on canarypox virus vector (ALVAC) or fowlpox (TROVAC) may be used as parent strains to create recombinant poxviruses.
The recombinant poxviruses may be utilised in compositions of the present invention so as to provide a capability to express an IL-4 antagonist (e.g. an IL-4Ra receptor antagonist) in a transient manner, for example, at a localised site of immunisation. When co-administered with an immunogenic component such as an antigen (e.g. encoded in the same or a separate poxvirus), the IL-4 antagonist may enhance the induction of antigen-specific immune cells (e.g. CD8⁺ T lymphocytes) with high avidity. Immune responses developed against the recombinant poxvirus will eventually clear the viruses, thus meaning that the IL-4 antagonist is expressed transiently rather than permanently, improving the safety profile.

In exemplary embodiments, compositions of the present invention may comprise one or a series of recombinant vaccinia and/or fowlpox viruses. The recombinant virus(es) may comprise exogenous polynucleotide sequence(s) encoding an IL-4 antagonist (e.g. an IL-4Ra receptor antagonist), at least one antigen from an infectious microorganism (e.g. a pathogenic virus), or both. The antigen may be a viral antigen (e.g. a retroviral antigen). The antigen may be an antigen from HIV-1 and/or HIV-2. The antigen may be encoded by any one or more of the gpl20 env, gpl40 env, gpl60 env, p18, gag, pol, vif, vpr, vpu, tat, rev, and nef genes, or combinations thereof. The IL-4 antagonist may be a mutant form of IL-4 comprising a mutation that renders it capable of binding to IL-4Ra without initiating cell signalling. For example, the mutation(s) may be at residue 121 and/or 124 (e.g. R121D and/or Y124D of the mature secreted human form of IL-4) or a corresponding position in an IL-4 homolog from another species. The mutation(s) may be a deletion of some or all residues encoded by exon 2 of the IL-4 gene.

-formulations, medicaments and vaccines

Compositions and medicaments of the present invention may be prepared using methods known to those of ordinary skill in the art. Non-limiting examples of suitable methods are described in Gennaro et al. (Eds), (1990), "Remington's Pharmaceutical Sciences", Mack Publishing Co., Easton, Pennsylvania, USA.

Compositions and medicaments of the present invention may comprise a pharmaceutically acceptable carrier, excipient, diluent and/or adjuvant. "Pharmaceutically acceptable" carriers, excipients, diluents and/or adjuvants as contemplated herein are substances which in general do not produce significant adverse reaction(s) when administered to a particular recipient such as a human or non-human animal. Pharmaceutically acceptable carriers, excipients, diluents, and adjuvants are generally also compatible with other ingredients of the composition or medicament. Non-limiting

Compositions and medicaments of the present invention may be formulated as vaccines. Vaccines of the present invention include both preventative vaccines (i.e. vaccines administered for the purpose of preventing infection) and therapeutic vaccines (i.e. vaccines administered for the purpose of treating infection). A vaccine of the present invention may therefore be administered to a recipient for prophylactic, ameliorative, palliative, or therapeutic purposes.

Compositions and medicaments of the present invention may be in a form suitable for administration by injection, in a formulation suitable for oral ingestion (such as, for example, capsules, tablets, caplets, elixirs), in the form of an ointment, cream or lotion suitable for topical administration, in a form suitable for delivery as an eye drop, in an aerosol form suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation, or in a form suitable for parenteral administration, that is, subcutaneous, intramuscular or intravenous injection.

Supplementary active ingredients such as adjuvants or biological response modifiers can also be incorporated into compositions and medicaments of the present invention. Although adjuvant(s) may be included in pharmaceutical compositions of the present invention they need not necessarily comprise an adjuvant. In such cases, reactogenicity problems arising from the use of adjuvants may be avoided.

In general, adjuvant activity in the context of a composition or medicament of the present invention includes, but is not limited to, an ability to enhance the immune response (quantitatively or qualitatively) induced by immunogenic components in the composition or medicament (e.g. an antigen). This may reduce the dose or level of the immunogenic components required to produce an immune response and/or reduce the number or the frequency of immunisations required to produce the desired immune response.

Any suitable adjuvant may be included in a composition or medicament of the present invention. For example, an aluminium-based adjuvant may be utilised. Suitable aluminium-based adjuvants include, but are not limited to, aluminium hydroxide, aluminium phosphate and combinations thereof. Other specific examples of aluminium-based adjuvants that may be utilised are described in European Patent No. 1216053 and United States Patent No. 6,372,223. Other suitable adjuvants include Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.); Merck Adjuvant
aluminium salts such as aluminium hydroxide gel (alum) or aluminium phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A; oil in water emulsions including those described in European Patent No. 0399843, United States Patent No. 7,029,678 and PCT Publication No. WO 2007/006939; and/or additional cytokines, such as GM-CSF or interleukin-2, -7, or -12, granulocyte-macrophage colony-stimulating factor (GM-CSF), monophosphoryl lipid A (MPL), cholera toxin (CT) or its constituent subunit, heat labile enterotoxin (LT) or its constituent subunit, toll-like receptor ligand adjuvants such as lipopolysaccharide (LPS) and derivatives thereof (e.g. monophosphoryl lipid A and 3-Deacylated monophosphoryl lipid A), muramyl dipeptide (MDP) and F protein of Respiratory Syncytial Virus (RSV).

Methods

The present invention provides methods for inducing antigen-specific immune responses in a subject. The methods may be effective for increasing the avidity of immune cells for an administered antigen and/or increasing the number of immune cells specific for an administered antigen in a subject. The methods may be conducted for prophylactic, ameliorative, palliative, and/or therapeutic purposes. For example, the methods may be used for preventing an infection in a subject (i.e. vaccination) and/or treating an infection in a subject (e.g. viral infections, retroviral infections, HIV-1 and/or HIV-2 infection).

The methods require administration of one or more compositions, medicaments or vaccines of the present invention. Accordingly, the methods require the administration of an IL-4 antagonist such as, for example, any one or more of those described in the section above entitled "Interleukin-4 (IL-4) antagonists". For example, the methods may comprise administering an antagonist that binds to IL-4, or an IL-4R antagonist such as an antagonist that binds to IL-4Ra. The methods also require the administration of an immunogenic component, such as a component comprising one or more antigens. Non-limiting examples of suitable antigens include any one or more of those described in the section above entitled "Antigens". The antigen may be derived from a pathogenic microorganism such as a virus. For example, the methods may comprise administering an antigen from HIV-1 and/or HIV-2, including antigen(s) encoded by any one or more of
the gpl20 env, gpl40 env, gpl60 env, pl8, gag, pol, vif, vpr, vpu, tat, rev, and nef genes, and combinations thereof (e.g. gag/pol, gag/pol/env).

The methods may involve simultaneous administration of the IL-4 antagonist(s) and immunogenic component(s), or, involve sequential administration of the IL-4 antagonist(s) followed by the immunogenic component(s) (or vice versa). When administered simultaneously, the IL-4 antagonist(s) and immunogenic component(s) may be provided in the same composition, or in separate compositions. The compositions may comprise one or more nucleic acid constructs or recombinant viruses comprising polynucleotide sequence(s) encoding the IL-4 antagonist(s) and/or immunogenic component(s) (e.g. one or more recombinant poxviruses such as a recombinant vaccinia virus, recombinant fowlpox virus, and/or a recombinant MVA virus). Non-limiting examples of suitable nucleic acid constructs and recombinant viruses are set out above in the subsections entitled "nucleic acid constructs", "recombinant viruses" and "exemplary recombinant viruses".

The present inventors have identified that the magnitude of antigen-specific immune cell responses and/or the avidity of immune cells for an antigen may be further improved by transient antagonism of IL-4/IL-4R signalling in the local milieu of an immune response to the antigen. For example, the generation of high avidity antigen-specific immune cells (e.g. memory CD8+ T cells) may be improved by transient expression (e.g. for a period of less than 1, 2, 3, 4, 5, 6, 7, 14 or 21 days) of an IL-4 antagonist (e.g. an IL-4Ra antagonist) upon initial administration of the antigen.

Exemplary formulations for administration are described in the subsection above entitled "formulations and vaccines". Exemplary dosages and routes of administration are described in the section below entitled "Dosages and routes of administration".

In general, the compositions, medicaments and vaccines are administered to the subject in a therapeutically effective amount. A "therapeutically effective amount" includes within its meaning a non-toxic but sufficient amount of the active component(s) for use in the present invention to provide the desired therapeutic effect. The exact amount required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the nature of the infection being prevented, the particular agent being administered, the mode of administration, and so forth. Thus, it is not possible to specify an exact "therapeutically effective amount". However, for any given case, an appropriate "therapeutically effective amount" may be determined by one of ordinary skill in the art using only routine experimentation.
"Subjects" as contemplated herein include mammals (e.g. humans) and individuals of any species of social, economic or research importance including, but not limited to, ovine, bovine, equine, porcine, feline, canine, avian, primate, and rodent species.

The methods of the present invention may be used to induce an antigen-specific immune response in a subject against an antigen co-administered with an IL-4 antagonist. The antigen-specific immune response may comprise T lymphocytes (e.g. CD8+ T lymphocytes). It will be understood that "inducing" an antigen-specific immune response as contemplated herein includes inciting an immune response as well as modulating a previously existing immune response (e.g. enhancing or existing immune response). Co-administration of the antigen with an IL-4 antagonist may enhance immune responses specific for the antigen above those achieved by administration of the antigen without the IL-4 antagonist.

Additionally or alternatively, the methods of present invention may be used to increase the avidity of immune cells for an antigen co-administered to a subject with an IL-4 antagonist. The immune cell may be a T lymphocyte (e.g. a CD8+ T lymphocyte). By increasing the immune cell avidity for the antigen, the quantity or concentration of the antigen required to elicit a response in the immune cell/immune cell population is decreased. Co-administration of the antigen with an IL-4 antagonist may enhance avidity of the immune cell for the antigen above the avidity that would be achieved by administration of the antigen without the IL-4 antagonist.

Additionally or alternatively, the methods of present invention may be used to increase the number of immune cells specific for an antigen in a subject. The immune cell may be a T lymphocyte (e.g. a CD8+ T lymphocyte). Co-administration of the antigen with an IL-4 antagonist may increase the number of immune cells specific for the antigen above the number that would be achieved by administration of the antigen without the IL-4 antagonist.

The induction of antigen-specific immune responses and the number and avidity of antigen-specific immune cells can be determined using standard methods known to those skilled in the field. Exemplary methods include, but are not limited to, solid-phase heterogeneous assays (e.g. enzyme-linked immunosorbent assay), solution phase assays (e.g. electrochemiluminescence assay), amplified luminescent proximity homogeneous assays, flow cytometry, intracellular cytokine staining, functional T-cell assays, functional B-cell assays, functional monocyte-macrophage assays, tetramer binding and dissociation assays, pentamer binding and dissociation assays, dendritic and reticular
endothelial cell assays, measurement of NK cell responses, oxidative burst assays, cytotoxic-specific cell lysis assays, and phagocytosis and apoptosis evaluation.

The methods may comprise administering a priming dose of the antigen and interleukin-4 receptor antagonist, and subsequently administering a later booster dose of the antigen and interleukin-4 receptor antagonist. For example, the booster dose may be administered at least 7, 14, 21 or 28 days, at least 1, 2, 3, 4, 5, or 6 months, or at least 1, 2, 3, 4, or 5 years after the priming dose. The antigen and IL-4 antagonist of the priming vaccine dose may be administered separately or sequentially. The antigen and IL-4 antagonist of the booster dose may be administered separately or sequentially. The priming and booster dose may be administered by the same or different routes. For example, the priming and booster doses may both be administered mucosally (e.g. intranasally), intramuscularly, intravenously or subcutaneously. Alternatively, the priming dose may be administered mucosally (e.g. intranasally) to induce mucosal antigen-specific immune cells, and the booster dose administered intramuscularly, subcutaneously or intravenously to induce systemic antigen-specific immune cells.

**Dosages and routes of administration**

Compositions, medicaments and vaccines of the present invention can be administered to a recipient by standard routes, including, but not limited to, parenteral (e.g. intravenous, intraspinal, subcutaneous or intramuscular), oral, topical, or mucosal routes (e.g. intranasal).

The compositions, medicaments and vaccines may be administered to a recipient in isolation or in combination with other additional therapeutic agent(s). In embodiments where they are administered with therapeutic agent(s), the administration may be simultaneous or sequential (i.e. composition/medicament/vaccine administration followed by administration of the agent(s) or vice versa).

In general, the compositions, medicaments and vaccines may be formulated in a manner compatible with the route of administration and physical characteristics of the recipient (including health status) and in such a way that it elicits the desired effect(s) (i.e. therapeutically effective, immunogenic and/or protective). For example, the appropriate dosage of compositions, medicaments and vaccines of the present invention may depend on a variety of factors including, but not limited to, a subject's physical characteristics (e.g. age, weight, sex), whether the composition, medicament or vaccine is being used as single agent or adjuvant therapy, the type of MHC restriction of the patient, the progression (i.e. pathological state) of a virus infection, and other factors that may be
recognized by one skilled in the art. Various general considerations that may be considered when determining an appropriate dosage are described, for example, in Gennaro et al. (Eds), (1990), "Remington's Pharmaceutical Sciences", Mack Publishing Co., Easton, Pennsylvania, USA; and Gilman et al., (Eds), (1990), "Goodman And Gilman's: The Pharmacological Bases of Therapeutics", Pergamon Press.

One skilled in the art would be able, by routine experimentation, to determine an effective, non-toxic amount of an antigen and/or an IL-4 antagonist as described herein to include in a composition, medicament or vaccine of the present invention for the desired therapeutic outcome. In general, a composition, medicament or vaccine of the present invention may be administered to a patient in an amount of from about 50 micrograms to about 5 mg of active component(s). Dosage may be in an amount of from about 50 micrograms to about 500 micrograms of active component(s). Generally, an effective dosage is expected to be in the range of about 0.001 mg to about 1000 mg of active component(s) per kg body weight per 24 hours; typically, about 0.01 mg to about 750 mg per kg body weight per 24 hours; about 0.01 mg to about 500 mg per kg body weight per 24 hours; about 0.1 mg to about 250 mg per kg body weight per 24 hours; about 1 mg to about 100 mg per kg body weight per 24 hours. More typically, an effective dose range is expected to be in the range about 1 mg to about 200 mg per kg body weight per 24 hours; about 1 mg to about 100 mg per kg body weight per 24 hours; about 1 mg to about 50 mg per kg body weight per 24 hours; about 0.5 mg to about 25 mg per kg body weight per 24 hours; about 0.1 mg to about 10 mg per kg body weight per 24 hours; about 0.1 mg to about 5 mg per kg body weight per 24 hours; or about 0.1 mg to about 2.5 mg per kg body weight per 24 hours.

 Typically, in treatment applications, the treatment may be for the duration of the disease state or condition. Further, it will be apparent to one of ordinary skill in the art that the optimal quantity and spacing of individual dosages will be determined by the nature and extent of the disease state or condition being treated, the form, route and site of administration, and the nature of the particular individual being treated. Optimum conditions can be determined using conventional techniques.

 In many instances (e.g. preventative applications), it may be desirable to have several or multiple administrations of a composition, medicament or vaccine of the present invention. For example, the composition, medicament or vaccine may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times. The administrations may be from about one to about twelve week intervals, and in certain embodiments from about one to
about four week intervals. Periodic re-administration may be desirable in the case of recurrent exposure to a particular antigen targeted.

It will also be apparent to one of ordinary skill in the art that the optimal course of administration can be ascertained using conventional course of treatment determination tests.

Where two or more entities are administered to a subject "in conjunction", they may be administered in a single composition at the same time, or in separate compositions at the same time, or in separate compositions separated in time.

Certain embodiments of the present invention involve the administration of composition, medicament or vaccines in multiple separate doses. Accordingly, the methods for the prevention (i.e. vaccination) and treatment of infection described herein encompass the administration of multiple separated doses to a subject, for example, over a defined period of time. Accordingly, the methods for the prevention (i.e. vaccination) and treatment of infection disclosed herein include administering a priming dose. The priming dose may be followed by a booster dose. The booster dose may be for the purpose of re-vaccination. In various embodiments, the composition, medicament or vaccine is administered at least once, twice, three times or more.

**Kits**

Agent(s) suitable for performing the methods of the present invention, including compositions, medicaments and vaccines, may be provided as component(s) in kits.

Kits of the present invention may comprise components to assist in performing the methods of the present invention such as, for example, administration device(s), buffer(s), and/or diluent(s). The kits may include containers for housing the various components and instructions for using the kit components in the methods of the present invention.

The kits may be fragmented kits or combined kits as defined herein. Fragmented kits comprise reagents are housed in separate containers, and may include small glass containers, plastic containers etc. Such containers may allow the efficient transfer of reagents from one compartment to another compartment whilst avoiding cross-contamination of reagents, and the addition of agents or solutions of each container from one compartment to another in a quantitative fashion. Typically, a kit of the present invention will also include instructions for using the kit components to conduct the appropriate methods.

For example, the kit may comprise a first container and second container. The first container may comprise an IL-4 antagonist (e.g. such as an antagonist that binds to IL-
4Ra). The second container may comprise components comprising or encoding an immunogenic agent (e.g. one or more viral antigens). The kits may also comprise one or more other containers, containing for example, one or more devices to assist in administering component(s) of the kit to a subject as required to perform the methods of the invention.

It will be appreciated by persons of ordinary skill in the art that numerous variations and/or modifications can be made to the present invention as disclosed in the specific embodiments without departing from the spirit or scope of the present invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Examples

The present invention will now be described with reference to the following specific examples, which should not be construed as in any way limiting on the scope of the invention.

Example 1: preparation of vaccines

- Design and preparation of murine IL-4 mutant sequences

Mouse IL-4C1 18 cDNA was amplified from total spleen RNA using gene specific primers and the One-Step RT-PCR kit (QIAGEN).

Forward primer 5' GGATCCACCATGGGCTCTCAACCCCCAGCTA 3' (SEQ ID NO: 1) contained a BamHI (GGATCC) restriction site to facilitate cloning and a consensus Kozak translation initiation sequence (CCACCATGG) overlapping the methionine start codon.

Reverse primer 5' GAATTCTAATCCATTTGATGATGCTC 3' (SEQ ID NO: 2) contained the insertion of an in-frame STOP codon (TAG) to prematurely terminate the amino acid sequence after position 118 on the mature secreted protein, which lacks the 20 amino acid signal peptide encoded by the complete gene sequence. Amino acid 118 of the mature secreted protein thus corresponds to codon position 138 of the complete gene sequence (which includes the amino terminal cleavable signal peptide). Insertion of the stop codon creates a deletion of the two terminal amino acids 119 & 120 removing the essential Tyrosine at position 119 required for cell signalling. The reverse primer also contains an EcoRI restriction site to facilitate DNA sub-cloning.
The 431 bp PCR fragment (SEQ ID NO: 3) was directly ligated into the U-tailed vector pDrive and transformed into QIAGEN EZ competent cells (QIAGEN). The PCR fragment was subcloned between the BamHI and EcoRI sites of pBluescriptSK+, to add a downstream HindIII site, and then subcloned as a BamHI-HindIII fragment into pAF09 (see Reference 7) in-frame with the fowlpox virus early/late promoter ATG codon contained in the vector. The mouse IL-4C1 18 BamHI-HindIII fragment was also subcloned into pTK7.5A (see Reference 9) downstream of the vaccinia virus P7.5 early/late promoter.

- Construction of FPV-HIV and VV-HIV vaccines co-expressing IL-4C118

Recombinant viruses co-expressing the HIV gag/pol(mut) antigen and mouse IL-4C1 18 were constructed using parent viruses FPV-HIV 086 and VV-HIV 336 (see Reference 1). Recombinant FPV was constructed by infecting chicken embryo skin (CES) cell cultures with FPV-HIV 086 (MOI 0.05) followed by transfection with pAF09-IL-4C1 18 using Lipofectamine 2000 (Invitrogen, USA). rFPV were selected by passage of viruses on CES cells in the minimal essential media (MEM) containing MX-HAT (2.5 mg/ml mycophenolic acid, 250 mg/ml xanthine, 100 mg/ml hypoxanthine, 0.4 mg/ml aminopterine and 30 mg/ml thymidine) to select for viruses expressing the gpt (xanthine guanine phosphoribosyltransferase) gene. Plaques containing recombinant viruses were identified using an agar overlay (1% agar in MEM) containing X-gal (200 mg/ml) to detect co-expression of the IacZ gene. Blue staining plaques were picked and 3 to 4 plaque purification rounds were performed under selection media. Recombinant viruses were confirmed by PCR for the presence of the IL-4C1 18 gene and absence for wild-type virus.

Similarly, rVV were constructed by infecting H143B TK-cells with VV-336 (MOI 0.05) and transfection with pTK7.5A- IL-4C1 18. Recombinant viruses were selected using MEM containing HAT supplement to select for viruses expressing the Herpes Simplex Virus TK gene contained in the vector. Viruses were plaque purified under selection and purity confirmed similar to rFPV.

Recombinant FPV-092 (HIV gagpol and env) and VV337 (HIV env) (see Reference 1) co-expressing mouse IL-4C1 18 were similarly constructed using the above methods.

A brief summary description of the IL-4C1 18 recombinant viruses produced is provided below. As noted above, the construction of each is described in Reference 1, and each is commercially available from the CSIRO biological reagents catalogue (see: http://asnet 1-mi.act.csiro.au/index.aspx).
(i) FPV086 is a recombinant fowlpox virus expressing HIV-1 subtype B gagpol (with specific mutations) under the control of PE/L (fpv early/late) and inserted in the F6,7,9 locus of FPV-M3 using pKG10a;

(ii) VV336 is a TK negative recombinant vaccinia virus expressing HIV subtype A/E gagpol (with specific mutations) under the control of PE/L (fpv early/late) inserted in the TK locus of VV-WR-L929 using pJmcs;

(iii) FPV092 is a recombinant fowlpox virus expressing HIV-1 subtype AE gagpol (with specific mutations) under the control of PE/L (fpv early/late) and inserted in the F6,7,9 locus of FPV-090 (AE env) using pKG10a;

(iv) VV337 is a TK negative recombinant vaccinia virus expressing HIV subtype A/E env (with specific mutations) under the control of PE/L (fpv early/late) inserted in the TK locus of W-WR-L929 using pJmcs.

- Macaque IL4C123 vaccine

The natural macaque IL-4 cDNA sequence was obtained from the GenBank database (see entry under GenBank/NCBI Reference Sequence: NM_001032904 - SEQ ID NOs: 8-9). A synthetic DNA sequence was designed (SEQ ID NO: 4) so that a stop codon was introduced immediately following amino acid 123 on the mature secreted protein, deleting the carboxyl-terminal sequences from the recombinant mutant protein. By analogy with the mouse and human IL4 proteins the essential Tyrosine at position 124 required for cell signalling was deleted.

The DNA sequence was modified as follows. A unique upstream sequence containing a BamHI site and a Kozak sequence was included to facilitate subcloning and ensure efficient translation of the protein respectively. A HindIII site was also included at the 3’ end to facilitate cloning into expression vectors. The DNA sequence was synthesised to order by Genscript USA Inc. The synthetic DNA was subcloned between the BamHI and HindIII sites of pAF09 as described above and recombinant fowlpox viruses isolated using FPV089 encoding the SIV gagpol gene. FPV089 is a recombinant fowlpox virus expressing SIV gagpol under the control of PE/L (fpv early/late) and inserted in the F6,7,9 locus of FPV-M3 using pKG10a. The construction of FPV089 is described in Reference 1, and it is commercially available from the CSIRO biological reagents catalogue (see: http://asnetl-mi.act.csiro.au/index.aspx).

For insertion and expression of the macaque IL-4C123 and SIV gag/pol genes into Modified vaccinia Ankara virus a series of new vectors were developed based on the MVA "del-III" (Figure 1 - SEQ ID NO: 10) and vaccinia "HindIII-F regions" (Figure 2...
- SEQ ID NO: 11) using a GFP-blasticidin S deaminase (BSD) fusion gene as a selectable marker gene (see Reference 8) utilising intergenic insertion sites (see Figures 1 and 2). A synthetic SIV mac239 gag/pol sequence was used that is optimised for expression in macaque monkeys (Figure 3 - SEQ ID NO: 12). The sequence contains a synthetic poxvirus early/late promoter upstream of the genes and an early transcription terminator sequence (T5NT) downstream flanked by restriction endonuclease site to facilitate cloning. The genes are expressed as a fusion protein resulting from a frame-shift during translation in the overlapping region.

It is envisaged and predicted that the Macaque IL4C123 vaccine produced above will induce improved immune responses against SIV in macaques administered the vaccine, compared to, for example, a similar or identical vaccine comprising the SIVgagpol gene without the mutant IL-4 sequence generated. More specifically, it is envisaged and predicted that the vaccine will induce improved antigen-specific T cell avidity and/or an improved magnitude of antigen-specific T cell responses against the SIV gagpol gene product.

- Design of human IL-4 mutant sequences

Human IL-4 sequences were also designed with a mutation at residue 123, in view of the high levels of sequence homology between the IL-4 gene and protein in macaques and humans.

A non-limiting example of a human IL-4 mRNA sequence is provided in GenBank/NCBI Reference Sequence: NM_000589.2. SEQ ID NO: 13 provides mRNA and amino acid sequences for the mature secreted form of human IL-4.

SEQ ID NO: 5 provides a human IL-4 DNA sequence encoding a mutant IL-4 protein (IL-4C123). The human IL-4C123 was designed by incorporating a stop codon (TGA) at codon position 148 so that the protein will be terminated after amino acid position 123 on the mature secreted protein following deletion of the 24 amino acid signal peptide. Amino acid position one on the mature secreted protein corresponds to codon position 25 on the mRNA. This will result in the generation of a mutant IL-4 lacking the essential Tyrosine at position 124 required for cell signalling. It is envisaged and expected that his protein will bind to both the type I and type II IL-4R without signalling preventing activation by endogenous IL-4 and IL-13.

The sequence above has been optimised for enhancing expression in human cells when used in the context of a vaccine (SEQ ID NO: 6). Codon optimisation resulted in the generation of a rare Fse1 restriction site (GGCCGGCC). This restriction site is used
during the sub-cloning process into the fowlpox and MVA vectors so was removed from the proposed optimised human IL4C123 sequence without changing the amino acid sequence (SEQ ID NO: 7).

It is envisaged and predicted that the human IL-4 protein mutants encoded by these sequences will be IL-4 receptor antagonists capable of binding to the IL-4 receptor without initiating IL-4 receptor-mediated cell signalling to any significant extent.

Moreover, it is envisaged and predicted that a human vaccine comprising any one or more of the human IL-4 protein sequences in combination with an antigen/antigen-encoding sequence will induce improved immune responses against the antigen in a human administered the vaccine, compared to, for example, a human administered a similar or identical vaccine comprising the antigen/antigen-encoding without the human IL-4 protein mutant(s). More specifically, it is envisaged and predicted that such a human vaccine will induce improved antigen-specific T cell avidity and/or an improved magnitude of antigen-specific T cell responses in a human to which it is administered.

Example 2: IL-4 antagonist vaccination induces high avidity CD8+ T cells

(i) Materials and methods

- Immunization of mice: Pathogen free 6-7 week old female BALB/c (H-2d) mice were obtained from the Animal Breeding Establishment, John Curtin School of Medical Research (JCSMR). All animals were maintained and used in accordance with the Australian National University animal experimentation ethics guidelines. Mice were prime-boost immunized with 1 x 10^7 pfu rFPV followed by 1 x 10^7 pfu rVV expressing HIV-1 antigens or/and IL-4R antagonist as described in Table 1 under mild methoxyfluorane anesthesia two weeks apart using i.n./i.m. - combined mucosal systemic route of vaccination. To evaluate protective immunity at 6 weeks following booster vaccination mice were challenged intranasally with 75 plaque forming units (PFU) of influenza virus PR8 (A/Puerto Rico/8/1934(H1N1)) expressing the K^4Gag97-205 epitope of HIV in the neuraminidase stalk (higher dose compared to previous studies) as described in Ranasinghe et al 2011 (see Reference 2). This was constructed using reverse genetic technology (see References 3 and 4). Body weight was monitored for 10 days after challenge.
Table 1. Prime boost vaccine strategies used in this study.

<table>
<thead>
<tr>
<th>Prime</th>
<th>Boost</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  i.n. FPV-HIV</td>
<td>i.m. VV-HIV</td>
</tr>
<tr>
<td>2  i.n. FPV-HIV IL-4C118</td>
<td>i.m. VV-HIV</td>
</tr>
<tr>
<td>3  i.n. FPV-HIV</td>
<td>i.m. VV-HIV IL-4C118</td>
</tr>
<tr>
<td>4  i.n. FPV-HIVIL-IL-4C118</td>
<td>i.m. VV-HIV IL-4C118</td>
</tr>
</tbody>
</table>

All rFPV and rVV constructs encode HIV-1 gag/pol antigens. All the viruses described in Table 1 were constructed using FPV-086 and VV-336 expressing the HIV gag/pol(mut) proteins as described in Reference 1.

i.n. = intranasal, i.m. = intramuscular.

- **Tetramer stainings and dissociation assays:** Allophycocyanin-conjugated K\(^d\)Gagi\(^{97-205}\) tetramers were synthesised at the Bio-Molecular Resource Facility at The John Curtin School of Medical Research. 2 - 5 x 10\(^6\) splenocytes or mucosal lymphocytes were stained with anti-CD8a-FTTC antibody (BD PharMigen, San Diego, CA) and APC-conjugated K\(^d\)Gagi\(^{97-225}\)tetramer at room temperature and analysed as described previously (see References 2 and 5).

Similarly, following K\(^d\)Gagi\(^{97-205}\) tetramer staining the dissociation assays were performed as described previously (see Reference 2). Plates were configured to assess five time points per sample (0-60 min). 50 µg/ml of anti-H-2K\(^d\) competitive binding antibody (BD PharMigen, San Diego, USA) was added to each well to prevent dissociated tetramer from re-binding and plates were incubated at 37°C, 5%CG\(_2\). At each time point, cells were transferred into ice-cold FACS buffer to stop the reaction, washed and resuspended in 100 µl of FACS buffer containing 0.5% paraformaldehyde. 100,000 events were acquired on a FACs Calibur flow cytometer (Becton-Dickinson, San Diego, USA)) and analysed using Cell Quest Pro software.

- **IFN-γ and IL-2 ELISpot assay:** IFN-γ or IL-2 HIV-specific T cell responses were measured by IFN-γ or IL-2 capture ELISpot assay as described previously (see References 2 and 6). Briefly, 2x10\(^5\) spleen or GN cells were added to 96-well Millipore PVDF plates (Millipore, MA, Ireland) coated with 5 µg/ml of mouse anti- IFN-γ or IL-2 capture antibodies (BD PharMigen, San Diego, CA), and stimulated for 12 h or 22 h respectively for IL-2 or IFN-γ ELISpot, in the presence of H-2K\(^d\) immuno-dominant CD8+ T cell epitope, Gagi\(^{97-205}\) - AMQMLKETI (SEQ ID NO: 14) (synthesised at the Bio-Molecular Resource Facility at JCSMR). CohA-stimulated cells (Sigma, USA) were used as positive controls and unstimulated cells as negative controls. For both ELISpot
assays, all steps were carried out exactly as described previously (see References 2 and 5). Plotted data are expressed as SFU per 10^6 T cells and represent mean values ± SD. Unstimulated cell counts were subtracted from each stimulated value before plotting the data. All instances the background SFU counts were extremely low.

- **Intracellular cytokine analysis (ICS):** IFN-γ and TNF-oc producing HIV-specific CD8 T cells, were analysed as described in Ranasinghe et al. (see References 2 and 5). Briefly, 2 x 10^6 lymphocytes were stimulated with AMQMLKETI (SEQ ID NO: 14) peptide at 37°C for 16 h, and further incubated with Brefeldin A (eBioscience, CA, USA) for 4 h. Cells were surface-stained with CD8-APC (BD PharMigen, San Diego, CA) then fixed and permeabilized prior to intracellular staining with IFN-γ-FTTC and TNF-a-PE (BD PharMigen, San Diego, CA). Total 100,000 gated events per sample were collected using FACS Calibur flow cytometer (Becton Dickinson, San Diego, CA), and results were analysed using Cell Quest Pro software. Prior to plotting the graphs the unstimulated background values were subtracted from the data.

- **Statistical analysis of data:** SD or SEM was calculated and p-values determined using a two-tailed, two sample equal variance or unequal variance Student’s t-Test. The p-values less than 0.05 were considered significant. Unless stated otherwise experiments were repeated a minimum of three times.

(u) **Results**

- **HIV-1 vaccines that co-express IL-4 soluble antagonist can induce high avidity and high magnitude of systemic and mucosal HIV-specific CD8+ T cells:** The i.n./i.m. prime-boost immunization strategy was selected for these studies as HIV is a disease of the mucosae and sustained mucosal and systemic immunity are both desirable. The data indicates that prime-boosting with the HIV vaccines that co-expressed IL-4R antagonist (IL-4C1 18) (FPV-HIV- IL-4C1 18/ VV-HIV- IL-4C1 18) induced long lasting high avidity KαGag97.205-specific CTL (Figure 4). IL-4-/ mice vaccinated with FPVHIVgag/pol and VVHIVgag/ppol can generate high avidity CD8 T cells in 14 days but fail to generate high avidity memory CD8 T cells by 8 weeks. It is postulated that IL-4 is thus necessary in the cell milieu for normal immune function, whereas the transient inhibition of IL-4R with IL-4C1 18 is able to induce long lasting high avidity CTL with greater protection (Figure 9). The data also indicate that inclusion of IL-4C1 18 in the prime was advantageous in generating high avidity HIV-specific CD8 T cell subset (Figure 4).
contrast, if the receptor was only included in the booster immunization (i.n. FPV-HIV/ VV-HIV-IL-4C118) the T cell avidity was more similar to that of the control i.n. FPV-
HIV/ i.m. VV-HIV vaccination, even though elevated magnitude of HIV-specific CD8 T cells was observed (Figure 5).

i.n. FPV-HIV- IL-4C1 18/ i.m. VV-HIV- -IL-4C1 18 vaccine strategy also induced elevated IFN-γ producing systemic (Figure 6) and mucosal (Figure 7) K1Gag ip,20s-
specific CTL. More interestingly, the genito-rectal (mucosal) CTL producing enhanced IL-2 and IFN-γ (Figure 7) is an exciting prospect for a HIV vaccine as inducing IL-2 with vaccines of this nature can be a difficult task (normally multi-functionally, specifically
IL-2 production is considered as a hallmark of protective immunity). The IL-4 antagonist vaccine strategy is able to induce not only elevated HIV-specific effector T cell immunity but also memory CD8 T cells both in the systemic and mucosal compartments (Figure 9).

**- HIV-1 IL-4 antagonist vaccine strategy can generate robust protective immunity:** At 8 weeks following booster immunization, mice were challenged with 75 pfu of influenza virus expressing the K1Gag97-205 immunodominant epitope and body weights were monitored daily for 10 days. Mice maintaining body weight and not succumbing to influenza virus infection were considered as a measure of protective immunity (see Reference 2). Post challenge IL-13/- mice that received the control i.n FPV-HIV/i.m.
VV-HIV immunization did not lose significant body weight as opposed to the wild type BALB/c mice that receiving the same vaccine (Figure 8B). Interestingly, mice that received i.n. FPV-HIV-IL-4C1 18/ i.m. VV-HIV- IL-4C1 18 vaccines performed very similar to IL-13/- mice that received the control vaccines or mice tested with a soluble IL-13 inhibitor vaccine (i.n. FPV-HIV-IL-13RA10/ i.m. VV-HIV-IL-13RA10) (Figure 8A & 8B). From day five post challenge, the recovery rate of the above three vaccination groups was significantly higher compared to the wild type BALB/c mice that received the control vaccination p <0.05. The above protective data correlated well with the dissociation rates of CD8+ T splenocytes from IL-13/- mice given i.n. FPV-HIV/ i.m.
VV-HIV vaccine or the BALB/c mice that received i.n. FPV-HIV- IL-13RA10/ i.m. VV-
HIV- IL-13RA10 (Figure 4) and also the effector/memory mucosal and systemic immune responses observed (measured by IFN-γ and IL-2 production) (Figures 6, 7 and 9). The unimmunised mice showed up to 20-24% of body weight loss by day seven and showed signs of recovery by day ten post challenge (Figure 8B). At ten days IL-4 antagonist vaccine showed significantly higher IFN-γ responses compared to the control vaccination
strategy. Data clearly indicate that this IL-4 antagonist vaccine strategy can generate excellent protective immunity.

_**Magnitude and avidity of T cell responses induced by priming and/or booster IL-4 antagonist vaccines in mice:**_ Experiments were conducted to determine the effect of IL-4 antagonist administration on CD8^+ T cell avidity and magnitude at primary and/or booster vaccine stages.

T-cell responses were measured by tetramer staining. As shown in **Figure 5**, boosting with an HIV vaccine that co-express the IL-4 antagonist IL-4C1 18 [(i) FPV-HIV-IL-4C1 18/(ii) VV-HIV; or (i) FPV-HIV-IL-4C1 18/(ii) VV-HIV-IL-4C1 18] induced high avidity CTL. Priming and boosting with an HIV vaccine that co-express the IL-4 antagonist IL-4C1 18 [(i) FPV-HIV-IL-4C1 18/(ii) VV-HIV-IL-4C1 18] induces both high avidity and high magnitude CD8^+ T cell responses. However, delivering the IL-4 antagonist only in the booster dose [(i) FPV HIV/(ii) VV HIVIL-4C1 18] induced only a high magnitude of CD8^+ T cell responses but did not induce high avidity.

_**Systemic T cell responses induced by priming and booster IL-4 antagonist vaccines in mice:**_ Experiments were conducted to determine the level of systemic CD8^+ T cell immunity induced by priming and boosting with the IL-4 antagonist. As shown in **Figure 6**, intracellular cytokine staining indicates that IL-4 antagonist (IL-4C1 18) (grey bar) delivered in the prime and the booster vaccinations can enhance the induction of systemic HIV-specific CD8^+ IFN^y^+ T cells.

_**Mucosal T cell responses induced by priming and booster IL-4 antagonist vaccines in mice:**_ ELISPOT assays were conducted to determine the level of mucosal CD8^+ T cell immunity induced by priming and boosting with the IL-4 antagonist. As shown in **Figure 7**, the ELISPOT data indicates that IL-4 antagonist (IL-4C1 18) delivered in the prime and the booster vaccinations can enhance the induction of HIV-specific mucosal CD8^+ T cells that can express both IFN^y^+ and interleukin 2 (IL-2).

**Example 3: Evaluation of FPV HIV IL-4 antagonist vaccine**

**(i) Materials and methods**

_**Immunization of mice for lung antigen presenting studies:**_ Pathogen free 6-7 week old female BALB/c (H-2^K^) mice were obtained from the Animal Breeding Establishment,
John Curtin School of Medical Research (JCSMR). All animals were maintained and used in accordance with the Australian National University (ANU) animal experimentation ethics guidelines. Mice (n = 3-5) were intranasally immunized with 1 x 10^7 pfu the different recombinant FPV, VV or MVA HIV vaccine constructs (refer to Examples 1 and 2 above) under mild methoxyfluorane anaesthesia. Immediately prior to delivery the viruses were diluted in phosphate buffered saline (PBS) final volume of 25 μl/mouse and sonicated 20-30s to obtain an homogeneous viral suspension.

The FPV early/late promoter and HIV gagpol was amplified from FPV092 using the primers and PCR

FseI FPV el GGGCGGGCCATTTAGTATCCTAAAATTGAATTG
SalI KG 10a CTTTTTAAACAACC ATGGGTTCGAC

The product was ligated into the MVA vector along with the GFP-BSD cassette selection was used to construct the pMVA "F-site" described in Figure 2. Recombinant MVA-HIV gagpol was selected by Blasicidine resistance on chick skin cells and confirmed by GFP expression and PCR for gag.

-preparation of lung cell samples: Lung samples were first cut into small pieces and digested in 2 mL of complete RPMI buffer containing 2 mg/mL collagenase (Sigma, USA), 2.4 mg/mL dispase (GIBCO,USA), and 5 Units/mL DNase (Calbiochem, USA) at 37°C for 1 h with gentle vortexing. Sample was then filtered through a cell strainer, rinsed with complete RPMI, red cells lysed and filtered through sterile gauze to remove debris as described previously (see References 2, 10 and 11). The single cell suspensions was then kept at 4°C for minimum of 4-6 h for recovery prior to performing assays since we have observed that digestion can down regulate expression of some surface markers.

-evaluation of antigen presenting cells using FACS: BALB/c and IL-13 KO mice were immunised with control FPV-HIV and the other group of BALB/c mice were immunised with the different vaccines. 24 hours post-vaccination, mice were euthanized and lungs were collected and single cell suspensions were prepared as described above. From each sample 4 x 10^6 cells were aliquoted, and firstly cells were incubated with Fc block antibody (anti-mouse CD16/CD32 Fc Block, BD Biosciences, USA), for 20 min at 40°C and cells were surface stained for 30 min at 40°C with fluorescent labelled anti MHCII I-A^d, CD11c, CD11b, B220, CD8a, CD103 (Biolegend, USA or e-Biosciences, USA),
antibodies. Cells were fixed and total 500,000 gated events per sample were collected using Fortessa flow cytometer (Becton Dickinson, San Diego, CA), and results were analysed using Cell Quest Pro software.

- Immunization of mice for antibody studies: Pathogen free 6-7 week old female BALB/c (H-2d) mice were obtained from the Animal Breeding Establishment, John Curtin School of Medical Research (JCSMR). All animals were maintained and used in accordance with the Australian National University (ANU) animal experimentation ethics guidelines. Mice (n = 5) were prime-boost immunized with 1 x 10^7 pfu rFPV followed by 1 x 10^7 pfu rVV expressing HIV-1 antigens or/and IL-4 antagonist under mild methoxyfluorane anaesthesia two weeks apart using i.n./i.m. - combined mucosal systemic route of vaccination. Immediately prior to delivery rFPV and rVV were diluted in phosphate buffered saline (PBS) and sonicated 20-30s to obtain an homogeneous viral suspension, intranasal rFPV was given in a final volume of 20 - 25 µl and i.m. rFPV or rVV were delivered, 50 µl per quadriceps.

- Serum collection: Serum was collected from pre-immune mice, and also 2-8 weeks post booster immunisation. Blood was collected by tail vein puncture and serum was separated by centrifugation and stored at -20°C until assayed.

HIV-1 p24 Gag-specific serum Enzyme-linked Immunosorbent assay (ELISA): ELISA was used to determine HIV-1 p24 Gag-specific IgG1 and IgG2a serum antibody titres. Falcon Microtest HI plates (Becton Dickinson, Oxnard, CA) were coated with HIV-1 p24 Gag (kindly supplied by the NIH AIDS Research and Reference Reagent Program) in borate buffer (Pierce) overnight at 4°C. Plates were washed 5 times with 0.05% Tween20 in PBS (PBST), and non-specific binding sites were blocked by adding 5% skim milk/PBST, at 200 µl/well for 2 hours at 37°C. Plates were then washed as before, and serum samples diluted in 5% skim milk/PBST were added in a volume of 50 µl to each well. Serum samples were diluted two-fold from 1/50 to 1/400. Plates were incubated for 1.5 h at 37°C and washed as indicated with PBST. Secondary antibody, biotin-conjugated anti-mouse IgG1 or anti-mouse IgG2a (Southern Biotechnology Associates, Birmingham, AL) diluted to 1:500 in 1%, bovine serum albumin/ PBST (Sigma) (BSA/PBST) was added to respective wells in a 50 µl volume, and incubated overnight at 4°C. Plates were washed 5 times with PBST, and 50 µl of horseradish peroxidase-conjugated streptavidin (HRP-SA, Amersham Life Science) diluted 1:1000 in 1%
BSA/PBST was added to each well. Plates were incubated at 37°C for 1.5 h, washed 5 times with PBS and antibodies were detected using 0.01 mg/ml Tetramethyl-benzidine (TMB) (Sigma) substrate dissolved in dimethyl sulfoxide (Sigma) and diluted in TMB citrate/phosphate substrate buffer (Sigma). Optical densities (OD) in each well were read at 405 nm at 15 and 30 min.

(ii) Results

To assess how the intranasal IL-4 antagonist prime induces high avidity CD8 T cells following i.n. delivery, APC subsets in the lung mucosae were evaluated. BALB/c and IL-13/- mice (n = 3) were intranasally immunized as described above with the different vaccines. 24 hours post-immunisation lung harvested and cells were stained as described above.

Figure 10 provides a series of dotplots setting out the antigen presenting cell (APC) subset gating strategy used for evaluating APC subsets in lung mucosae. The FACS plots display cells pre-gated on live cells followed by doublet discrimination based on forward scatter (FSC) and side scatter (SSC), and gated on MHCII I-A^d+ and CD1 lc+ population, the top panel (R5 gate) Then using this MHCII I-A^d+CD1 lc+ gate lung APC subsets expressing various levels of CD1 lb, B220, CD103, CD8 were analysed.

CD103 associated antigen presenting cell subsets of lung mucosae from mice were evaluated 24 hours post priming vaccination. As shown in Figure 11 intranasal (i.n.) FPV-HIV-C1 18 delivery induced an elevated I-A^d+ CD1 lc+ CD1 lb+ CD103- APC subset and a reduced I-A^d+ CD1 lc+ CD1 lb- CD103+ population in the lung mucosae compared to wild type BALB/c mice or the IL-13 -/- (knock out) mice receiving the control vaccine. The data suggests that the I-A^d+ CD1 lc+ CD1 lb+ CD103- population plays an important role in inducing high avidity CTL. In general i.n. FPV prime induces an APC subset that expresses elevated CD1 lb and lower CD103 in the lung mucosae compared to rVV or rMVA vectors (upper panels).

B220 associated antigen presenting cell subsets were evaluated in lung mucosae 24 hours post-priming vaccination (Figure 12). Intranasal FPV-HIV-C1 18 delivery induced I-A^d+ CD1 lc+ CD1 lb+ B220- (see upper left population in far right panel of central row) antigen presenting cell subset in the lung mucosae compared to wild type BALB/c (top left panel) or IL-13-/ mice (central row, second panel from left) given the FPV-HIV control vaccine. Similarly, FPV-HIV-C1 18 delivery induced elevated APC subset that was I-A^d+ CD1 lc+ CD1 lb-CD8-. The intranasal recombinant FPV vectors induced lower
IA^4+ CD1^1c+ CD1 lb- B220+ compared to VV-HIV or MVA-HIV (see lower right population in far right panel of central row).

The top right arrow (a) in **Figure 12** highlights the importance of intranasal FPV priming compared to VV or MVA priming. The central right arrow (b) in **Figure 12** shows that intranasal delivery of the IL-4R antagonist adjuvanted FPV-HIV vaccine induces an excellent CD1^1l+B220- dendritic cell subset in lung mucosae, and that the FPV-HIV-C118 prime induces the highest IA^4+ CD1^lC+ CD1 lb+B220- dendritic cell percentage. The bottom right arrow in **Figure 12** (c) shows that intranasal delivery of VV enhanced the CD1lb- B200+ DC subset in the lung mucosae. The clearly demonstrates that intranasal FPV priming is beneficial to inducting high avidity CD8 T cells which are induced during the priming vaccination rather than the booster.

CD8-associated antigen presenting cell subsets in the lung mucosae were also evaluated 24 hours post priming vaccination (**Figure 13**). Intranasal FPV-HIV-C118 delivery induced a lower percentage of dendritic cells that were IA^4+ CD1 lc+ CD1 lb- CD8+ (lower right population in bottom right panel - arrow indicates CD1 lb-CD8+ cells) in the lung mucosae compared to wild type BALB/c (top left panel) or IL-13/-/ mice (bottom left panel) given the FPV-HIV control vaccine. Similarly, FPV-HIV-C118 delivery induced elevated APC subset that was IA^4+ CD1 lc+ CD1 lb+CD8- (bottom right panel - upper left population). Intranasal recombinant FPV-HIV, VV-HIV or MVA-HIV vaccination induced similar percentages of DC that were IA^4+ CD1 lc+ CD1 lb- CD8+, suggesting that the vector used did not influence this DC subset.

**Figure 14** demonstrates enhanced serum IgGl response to p24Gag following HIV IL-4R antagonist adjuvanted vaccination (2 weeks post booster vaccination). These responses are expected to increase over time as optimum antibody responses are observed 4-8 weeks post vaccination. The responses observed were much greater than IL-13 KO mice given the control vaccine or the group that received the IL-13Ra2 adjuvanted vaccine (Reference 11).

**(iii) Discussion**

These results and additional observations highlight at least the following points:

A. The novel FPV HIV IL-4 antagonist vaccine when delivered intranasally (i.n.) can recruit unique antigen presenting cell (APC) subsets to the lung mucosae 12-24h post vaccination which is most likely responsible for the induction of high avidity CTL. Data suggest that APC subset IAd+CD1 lC+CD1 lb+CD103'B220'CD8" induced following FPV-
HIV-IL-4 antagonist vaccines plays a critical role in modulating T cell avidity (Figures 10-13). These vaccines behave very similar to IL-13-/ mice given the control FPV-HIV vaccine (Figures 11-13). Current APC data clearly indicate that IL-4 and IL-13 depleted cell milieu can chemoattract unique APC subsets into the lung mucosae, promoting the induction of high avidity CD8 T cells;

B. intranasal rFPV prime can recruit different APC subsets to the lung mucosae compared to recombinant vaccinia or modified vaccinia ankara (MVA) suggesting that the priming vector also plays an important role in modulating avidity (fig 1-3). Specifically, IAd+CD1 lc+CD1 lbCD103+ population induced following VV and MVA appears to have a negative implication on avidity;

C. rFPV is an excellent safe intranasal delivery vector and it does not cross the blood-brain barrier in mice (data not shown).

D. intranasal FPV HIV IL-4 antagonist (Cl 18) prime/ i.m. VV HIV CI 18 booster vaccination strategy can also induce elevated p24 gag IgGl antibody responses even at 2 week post booster vaccination. These responses will normally enhance further 4-8 weeks post booster vaccination.

References for Examples 1, 2 and 3


CLAIMS

1. A method for inducing an antigen-specific immune response in a subject, the method comprising administering the antigen to the subject in combination with an interleukin-4 receptor (IL-4R) antagonist.

2. A method for increasing the avidity of immune cells for an antigen in a subject, the method comprising administering the antigen to the subject in combination with an interleukin-4 receptor (IL-4R) antagonist.

3. A method for increasing the number of immune cells specific for an antigen in a subject, the method comprising administering the antigen to the subject in combination with an interleukin-4 receptor (IL-4R) antagonist.

4. The method according to claim 2 or claim 3, wherein the immune cell is a T-lymphocyte.

5. The method according to any one of claims 2 to 4, wherein the immune cell is a CD8+ T-lymphocyte.

6. The method according to any one of claims 1 to 5, wherein the antigen is a viral antigen.

7. The method according to any one of claims 1 to 6, wherein the antigen is a human immunodeficiency virus antigen.

8. The method according to any one of claims 1 to 7, wherein the antigen is a human immunodeficiency virus antigen selected from a gag, pol, or env gene product, or any combination thereof.

9. The method according to any one of claims 1 to 8, wherein the antigen and interleukin-4 receptor antagonist are administered to the subject sequentially.

10. The method according to any one of claims 1 to 8, wherein the antigen and interleukin-4 receptor antagonist are administered to the subject simultaneously.

11. The method according to any one of claims 1 to 10, wherein the antigen and interleukin-4 receptor antagonist are administered to the subject as a priming dose.

12. The method according to any one of claims 1 to 11, wherein said administering comprises administering a polynucleotide encoding the antigen, a polynucleotide encoding the interleukin-4 receptor antagonist, or both.

13. The method according to claim 12, wherein any one or more of said polynucleotides is a component of a recombinant virus.

14. The method according to any one of claims 1 to 13, wherein the IL-4R antagonist is an interleukin-4 receptor alpha chain (IL-4Ra) antagonist capable of binding to IL-4Ra and preventing IL-4R signalling.
26. The composition according to claim 24 or claim 25, wherein the antigen is a viral antigen.

27. The composition according to any one of claims 24 to 26, wherein the antigen is a human immunodeficiency virus antigen selected from a gag, pol, or env gene product, or any combination thereof.

28. The composition according to any one of claims 24 to 27, wherein the IL-4R antagonist is an interleukin-4 receptor alpha chain (IL-4Ra) antagonist capable of binding to IL-4Ra and preventing IL-4R signalling.

29. The composition according to any one of claims 24 to 28, wherein the IL-4R antagonist is a human interleukin-4 molecule lacking a signal peptide and comprising one or more mutations selected from: a mutation at residue 121, a mutation at residue 124, a deletion of one or more residues after position 123, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

30. The composition according to claim 29, wherein the mutation is selected from: R121D, Y124D, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

31. The composition according to any one of claims 24 to 30, wherein any one or more of said polynucleotides is a component of a recombinant virus.

32. The composition according to claim 31, wherein the recombinant virus is selected from the group consisting of a poxvirus, a vaccinia virus, an attenuated vaccinia virus (e.g. NYVAC), a fowlpox virus, a canarypox virus, and a modified vaccinia ankara (MVA) virus.

33. A method for preventing or treating an infection in a subject, the method comprising administering to the subject the composition according to any one of claims 24 to 32.

34. A method of vaccinating a subject against an infection, the method comprising administering a primer dose and a booster dose of the composition according to any one of claims 24 to 30 to the subject.

35. The method according to claim 33 or claim 34, wherein the infection is human immunodeficiency virus infection and the composition comprises a human immunodeficiency virus antigen selected from a gag, pol, or env gene product, or any combination thereof.

36. The method according to claim 13 or claim 20, wherein the recombinant virus is selected from the group consisting of a poxvirus, a vaccinia virus, an attenuated...
15. The method according to any one of claims 1 to 14, wherein the IL-4R antagonist is a human interleukin-4 molecule lacking a signal peptid and comprising one or more mutations selected from: a mutation at residue 121, a mutation at residue 124, a deletion of one or more residues after position 123, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

16. The method according to any one of claims 1 to 15, comprising administering a booster dose to the subject, wherein the booster dose comprises the antigen and an IL-4R antagonist.

17. The method according to claim 16, wherein the antigen and IL-4R antagonist of the booster dose are administered simultaneously.

18. The method according to claim 16, wherein the antigen and IL-4R antagonist of the booster dose are administered sequentially.

19. The method according to any one of claims 16 to 18, wherein administering the booster dose comprises administering a polynucleotide encoding the antigen, a polynucleotide encoding the IL-4R antagonist, or both.

20. The method according to claim 19, wherein any one or more of said polynucleotides is a component of a recombinant virus.

21. The method according to any one of claims 16 to 20, wherein the IL-4R antagonist is an interleukin-4 receptor alpha chain (IL-4Rct) antagonist capable of binding to IL-4Ra and preventing IL-4R signalling.

22. The method according to any one of claims 16 to 21, wherein the IL-4R antagonist of the booster dose is a human interleukin-4 molecule lacking a signal peptide and comprising one or more mutations selected from: a mutation at residue 121, a mutation at residue 124, a deletion of one or more residues after position 123, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

23. The method according to claim 15 or claim 22, wherein the mutation is selected from: R121D, Y124D, a deletion of a fragment encoded by exon 2 of an interleukin-4 gene, or any combination thereof.

24. A composition comprising:

(i) an antigen and/or a polynucleotide encoding the antigen; and

(ii) an interleukin-4 receptor (IL-4R) antagonist and/or a polynucleotide encoding the IL-4R antagonist.

25. The composition according to claim 24, wherein any one or more of said polynucleotides is a component of a recombinant virus.
vaccinia virus (e.g. NYVAC), a fowlpox virus, a canarypox virus, and a modified vaccinia ankara (MVA) virus.

37. The method according to claim 13, 20 or 36, wherein the recombinant virus transiently expresses the interleukin-4 receptor (IL-4R) antagonist in the subject.
501 TATGAGAAAA TTGCAAAATA TGGACACTCA TTTAACGGTA AAAGATTTAC GAAATGAGAA ATGTTGCTTA AGAATGATATA TCCAGAATT ATATCATATA

Ng0MIV

------

NaeI    PvuI

------

Bst1107I

------

FseI    AsiSI HindIII

------

BspHI    AccI

------

G:  ATCTCTCCACC AAAAAATGTTT TTITTTGCGG GCGCGGATCG CAAGCTTATG ATATATATAT CATCAATTCA TGATGTATA AC TACTGAGATA GTTTCAATGT

>......FSL......>

FshAI

----------

601 TGGGTTATGGA AATATTTTTA TTITTTATGTC CATTACTAAAT CGTATATTAT AATTGGAAAAT GGAATTAGTTT AATATGACGC

>>F7L.>

Tsp45I

------

701 GAACTTTTCCA CTTTCTTGCC GGTATGAAAG AAATATTTTTA TTITTTATGTC CATTACTAAAT CGTATATTAT AATTGGAAAAT GGAATTAGTTT AATATGACGC

----------

801 TCGTCTGAGG ATCTCTCTGCT GTGAGATTTG TGTACGGTAA GAAATAAAGAT AAGAGGGAAG ATGTAGGAGA GGAAGACAGAA GGAAGTTACA ATATATAAAGAA

>........................................F7L........................................

Sau96I

------

AflIII    BmgT1201

------

PmlI    AvalII

------

901 CCTTAATGAT CGGATGGAAT CCGAAGCACG TGTAAGATTG GCACATTATG ATACGATAAA TGAAGAAAAA TCGACATAAA ATACAGTTAGA TAAAAGAAA

>........................................F7L........................................

1001 AGATATAGAC AGACGATAGA GTCTCTATAT TTCTAAAGAT TTCTATATTTA AATGAGAAAA ATACTCGAGT TTGTATAAAA TAAGATAATT GACTGGATTA

----------
FIGURE TWO (cont)
FIGURE 3
961 AAGTCCCTGA GGGCCGAGCA GACGGAGGCC GCCGATGAAGA ACTGGATGAC CCAGACCCCTG
>........................gag........................>
1021 CTGATCCAGA ACGCCAACCC CGACTGCAAG CTGGTGCTGA AGGGGCTTGGG CGTGAACCC
>........................gag........................>
1081 ACCCTGGAGG AGATGCTGAC CGCCTGCCAG GGGGTGGGGG GCCCCGGCCA GAAGGCGAGG
>........................gag........................>
1141 CTGATGGCCG AGGCCCTGAA GGAGGCCCTG GCCTCCCCGTGC CCATCCCCCTG CGGCCGCGGCC
>........................gag........................>

EcoRI -----

1201 CAGCAGAGGG GCCCCAGGAA GCCCATCAAG TGCTGGAACG CGGCAAGGA GGCCCACTCC
>........................gag........................>

BsrDI |
-------|

1261 GCCAGGCAAT GCAGAGCCCC AAAGAAAGACG GAGATGTGGGA AATTGCGAAA AATGGACCCT
>........................gag........................>
>........................pol........................>

BbsI -----

1321 GTTATGGCCA AATGCCGAGA CAGACAGGGC CTTTTTTTAG GCCTGGGCCTG ATGGGGAAAG
>........................gag........................>
>........................pol........................>

SmlI -----
BpuEI -----

1381 AAGCCCGGCA ATTTCCCAT GGGTCAAGTG CATCAAGGGC TGATGCCAAC TGCTCCCCCA
>........................gag........................>
>........................pol........................>

1441 GAGGACCGAG CTGGTGATCT GCTAAAGAAC TACATGCAGT TGGGCAAGCA GCAGAGGAGA
>........................gag........................>
>........................pol........................>

1501 AAGCAGAGAG AAAGCAGGAG GAGGCTTAC AAGGGAGTGA CAGAGGATTG GCTGGACCTC
>........................gag........................>
>........................pol........................>

1561 AAATCTCTCT TGGAGGAGA CAGTAGTGA CGCAGCAGAT CGAGGCGAG CGGCTGGAGS
>........................gag........................>
>........................pol........................>

1621 TGCTGCTGGA CACCCGGGCC GACGACTCCA TGCGAAGCG CATCGAAGCTG GCGCCCCACT
>........................pol........................>

1681 ACAACCGCAA GATCGTGGGC GCCTCGGGG GCCCTCATCAA CACCAAGGAG TACAAGAACG
>........................pol........................>

BspHI -----

1741 TGGAGATCGA GGTGCTGGGC AAGGAGATCA AGGGCACCCT CATGAACCGGC GACACCCCA
>........................pol........................>

FIGURE 3 (cont)
FIGURE 3 (cont)
AGGAGGACAA GATCCTGAAG GTGGGCAAAGT TCGCCAAGAT CAAGAAGACC CACACCAAGG
>..........................pol............................>

GGTGGAGCT GCTGGCCAC GTGATCCGCA AGATCGGCAC GAGGCCGATC GTGATCGGAG
>..........................pol............................>

GCCAGGTGCA CAAGTTCCAC CTGCCGCTGG AGAAGGACGT GTGAGGCAG TGTTGGACCG
>..........................pol............................>

ACTACTGGCA GGTGACTGTT GATCCGGAGT GGGACTTCAT CTCCACCCCC CCCCCGCTGA
>..........................pol............................>

GGCTGGCTGT CAACTCGGGT AAGGACCCCA TCGGCGCGGA GGAAGCCTAC TACACCGAGC
>..........................pol............................>

GCTCCTGCAA CAGAGGATCC AAGGAGGGCA AGGCAGGCTA CATCACCCGAC AGGCGACAGG
>..........................pol............................>

ACAAGGTGCA GGTGCTGGAG CAGACACCAC AACCAGGCCG CGAGCTGGAG GCTTCCTGGA
>..........................pol............................>

TGGCCCTGAC CGACTCCTGG CCAAAGGCCA AACATCATCG GGACTCCCAG TACGCTAGG
>..........................pol............................>

GCATCATCAC CGCTGCCCC ACCGAGTCCG AGTCCAGGCT GTGGAACCG ATCCTCGAGG
>..........................pol............................>

AGATGATCAA GAAGTCCGAG ATCTACGGT CGTGGGCTGC CGCCCAACAG GCATCGGCGG
>..........................pol............................>

GCAACCAGGA GATCGACCAC CTGGGTCACC AGGGCATCAG GCAGTGGCTG TCTCCTGGAGA
>..........................pol............................>

AGATCGGCC CGCCCGAGG AGACGGACAC AGTACCACCT CAACGTCAGG AGGCTGCTGT
>..........................pol............................>

TCAAGTCCGG CCTGCCAGGG ATCGTGGCCA GCCAGATGG GCCACACTCG GCAAGTGGCC
>..........................pol............................>

ACCAAAGGG CGAGGCTAC CAGGGCCAGG CCAACTCCQA CTTGGGCCAC TGGCAGATGG
>..........................pol............................>

ACTGCAACCA CCGTGGGGGC AAGATCATCA TCGTGCCGCT GCAGTGGGCC TCGGCTTCA
>..........................pol............................>

TCGAGGCGGA GGTGATCCCC CAGGAGACG GCAAGGACAG CGCCGTGCTC TCTGCTAGAC
>..........................pol............................>

TGCCGCGCAG GTGGCCCGTC ACCACCTGCA ACCACGACAA CGCGGGCCAC TCAGGCTCCC
>..........................pol............................>

AGAAGGTGCA GATGCTGGCC TGCTGGGCGG GCACTGAGCA CACCTCAGGC GTGCCCTACA
>..........................pol............................>

SfiI

--------------------

FIGURE 3 (cont)
FIGURE 3 (cont)
**FIGURE FOUR**

- FPV HIV IL-4C118/VV HIV L-4C118
- FPV HIV/VV HIV

* $p=0.010$

**FIGURE FIVE**

- FPV HIV/VV HIV
- FPV HIV IL-4C118/VV HIV
- FPV HIV/VV HIV IL-4C118
- FPV HIV IL-4C118/VV HIV IL-4C118

* $p=0.015$  ** $p=0.0006$
FIGURE SIX

FIGURE SEVEN
Figure Eight

(A) Graph showing % Weight loss over Days post Influenza-HIV Challenge. The legend includes:
- FPV HIVC118/VV HIVC118
- FPV HIVΔ10/VV HIVΔ10
- FPV HIV/VV HIV
- Unimmunized

Statistical significance: p < 0.05

(B) Graph showing changes in weight loss over Days post Influenza-HIV Challenge for FPV HIV/VV HIV (IL13−/−).

FIGURE EIGHT
FIGURE NINE
FIGURE ELEVEN
FIGURE THIRTEEN
FIGURE FOURTEEN
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

A61K 38/20 (2006.01)  A61K 39/00 (2006.01)  A61K 39/21 (2006.01)  A61P 31/00 (2006.01)  A61P 31/18 (2006.01)

B. FIELDS SEARCHED

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>🗺</td>
<td>Further documents are listed in the continuation of Box C 🗺</td>
<td>See patent family annex</td>
</tr>
</tbody>
</table>

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier application or patent but published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search: 27 June 2013
Date of mailing of the international search report: 27 June 2013

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN, ACT 2606, AUSTRALIA
Email address: pct@ipaustalia.gov.au
Facsimile No.: +61 2 6283 7999

Authorised officer

Christina van Broekhoven
AUSTRALIAN PATENT OFFICE
(ISO 9001 Quality Certified Service)
Telephone No. 0262833196
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 2011/003 138 A1 (The Australia National University) 13 January 2011 see [0007-0012], [0111-0117] and Fig. 16A and B</td>
<td>1-37</td>
</tr>
<tr>
<td>X</td>
<td>WO 2010/12051 1 A2 (Altair Therapeutics Inc. et al.) 21 October 2010 see [00193-4] and [00246-7]</td>
<td>1-6, 9-13, 16-20, 24-26, 31-34 and 36-37</td>
</tr>
</tbody>
</table>
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Publication Number</td>
<td>Publication Date</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(My 2009)
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Publication Number</td>
<td>Publication Date</td>
</tr>
<tr>
<td>EP 2137215 A2</td>
<td>30 Dec 2009</td>
</tr>
<tr>
<td>EP 2548889 A1</td>
<td>23 Jan 2013</td>
</tr>
<tr>
<td>JP 2008502366 A</td>
<td>31 Jan 2008</td>
</tr>
<tr>
<td>JP 4970258 B2</td>
<td>04 Jul 2012</td>
</tr>
<tr>
<td>JP 2008512985 A</td>
<td>01 May 2008</td>
</tr>
<tr>
<td>JP 2008515776 A</td>
<td>15 May 2008</td>
</tr>
<tr>
<td>JP 2010512402 A</td>
<td>22 Apr 2010</td>
</tr>
<tr>
<td>JP 2010527916 A</td>
<td>19 Aug 2010</td>
</tr>
<tr>
<td>JP 2011225574 A</td>
<td>10 Nov 2011</td>
</tr>
<tr>
<td>MX PA06014298 A</td>
<td>19 Feb 2007</td>
</tr>
<tr>
<td>MX PA06014299 A</td>
<td>19 Feb 2007</td>
</tr>
<tr>
<td>MX PA06014564 A</td>
<td>23 Mar 2007</td>
</tr>
<tr>
<td>MX 2009005725 A</td>
<td>24 Aug 2009</td>
</tr>
<tr>
<td>MX 2009011366 A</td>
<td>05 Nov 2009</td>
</tr>
<tr>
<td>NO 20065800 A</td>
<td>17 Jan 2007</td>
</tr>
<tr>
<td>NO 20070087 A</td>
<td>05 Jan 2007</td>
</tr>
<tr>
<td>NO 20070133 A</td>
<td>08 Jan 2007</td>
</tr>
<tr>
<td>NZ 551982 A</td>
<td>29 Oct 2010</td>
</tr>
<tr>
<td>NZ 582046 A</td>
<td>29 Jul 2011</td>
</tr>
<tr>
<td>NZ 586421 A</td>
<td>25 Nov 2011</td>
</tr>
<tr>
<td>PA 8778101 A1</td>
<td>19 Nov 2008</td>
</tr>
<tr>
<td>PE 01542009 A1</td>
<td>31 Mar 2009</td>
</tr>
<tr>
<td>RU 2006140793 A</td>
<td>20 Jul 2008</td>
</tr>
<tr>
<td>RU 2006142554 A</td>
<td>27 Jul 2008</td>
</tr>
<tr>
<td>RU 2006140096 A</td>
<td>20 Jul 2008</td>
</tr>
<tr>
<td>RU 2009120202 A</td>
<td>20 Jan 2011</td>
</tr>
<tr>
<td>RU 2009140134 A</td>
<td>27 May 2011</td>
</tr>
<tr>
<td>SG 135207 A1</td>
<td>28 Sep 2007</td>
</tr>
<tr>
<td>SG 155260 A1</td>
<td>30 Sep 2009</td>
</tr>
<tr>
<td>SG 166090 A1</td>
<td>29 Nov 2010</td>
</tr>
<tr>
<td>TW 200848429 A</td>
<td>16 Dec 2008</td>
</tr>
<tr>
<td>US 2006073 148 A1</td>
<td>06 Apr 2006</td>
</tr>
<tr>
<td>US 7501121 B2</td>
<td>10 Mar 2009</td>
</tr>
<tr>
<td>US 2006063228 A1</td>
<td>23 Mar 2006</td>
</tr>
<tr>
<td>US 7615213 B2</td>
<td>10 Nov 2009</td>
</tr>
</tbody>
</table>

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Publication Number</td>
<td>Publication Date</td>
</tr>
<tr>
<td>US 7943342 B2</td>
<td>17 May 2011</td>
</tr>
<tr>
<td>US 2010129360 A1</td>
<td>27 May 2010</td>
</tr>
<tr>
<td>US 2007048785 A1</td>
<td>01 Mar 2007</td>
</tr>
<tr>
<td>US 2009098142 A1</td>
<td>16 Apr 2009</td>
</tr>
<tr>
<td>US 2011262435 A1</td>
<td>27 Oct 2011</td>
</tr>
<tr>
<td>WO 2008073463 A2</td>
<td>19 Jun 2008</td>
</tr>
<tr>
<td>WO 2008131376 A2</td>
<td>30 Oct 2008</td>
</tr>
<tr>
<td>ZA 200610295 A</td>
<td>26 May 2010</td>
</tr>
</tbody>
</table>

End of Annex